IL95675A - N-aryl-pyrazole derivatives processes for their preparation and pharmaceutical compositions containing them - Google Patents
N-aryl-pyrazole derivatives processes for their preparation and pharmaceutical compositions containing themInfo
- Publication number
- IL95675A IL95675A IL9567590A IL9567590A IL95675A IL 95675 A IL95675 A IL 95675A IL 9567590 A IL9567590 A IL 9567590A IL 9567590 A IL9567590 A IL 9567590A IL 95675 A IL95675 A IL 95675A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- salt
- formula
- phenyl
- substituted
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 6
- 238000000034 method Methods 0.000 title abstract description 76
- 238000002360 preparation method Methods 0.000 title abstract description 21
- 150000001875 compounds Chemical class 0.000 claims abstract description 205
- 150000003839 salts Chemical class 0.000 claims abstract description 190
- -1 nitro, amino Chemical group 0.000 claims abstract description 140
- 125000003118 aryl group Chemical group 0.000 claims abstract description 68
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 55
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 44
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims abstract description 42
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract description 42
- 125000002252 acyl group Chemical group 0.000 claims abstract description 39
- 125000004442 acylamino group Chemical group 0.000 claims abstract description 36
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims abstract description 33
- 125000003282 alkyl amino group Chemical group 0.000 claims abstract description 29
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 27
- 150000002367 halogens Chemical class 0.000 claims abstract description 27
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 27
- 125000001424 substituent group Chemical group 0.000 claims abstract description 20
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 11
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims abstract description 10
- 125000004423 acyloxy group Chemical group 0.000 claims abstract description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
- 239000001257 hydrogen Substances 0.000 claims abstract description 5
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 94
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 20
- 125000001544 thienyl group Chemical group 0.000 claims description 14
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 150000004820 halides Chemical class 0.000 claims description 7
- 238000006460 hydrolysis reaction Methods 0.000 claims description 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 5
- 238000005917 acylation reaction Methods 0.000 claims description 4
- 238000005947 deacylation reaction Methods 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 238000005804 alkylation reaction Methods 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- NKBRWXWNSUIHNI-UHFFFAOYSA-N 1-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)pyrazole-3-carbonitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C#N)=NN1C1=CC=C(F)C=C1 NKBRWXWNSUIHNI-UHFFFAOYSA-N 0.000 claims description 2
- 125000001589 carboacyl group Chemical group 0.000 claims description 2
- 238000007257 deesterification reaction Methods 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims 2
- MDYRNALVHHWDBA-UHFFFAOYSA-N 1-(4-fluorophenyl)-5-(4-methylsulfinylphenyl)pyrazole-3-carbonitrile Chemical compound C1=CC(S(=O)C)=CC=C1C1=CC(C#N)=NN1C1=CC=C(F)C=C1 MDYRNALVHHWDBA-UHFFFAOYSA-N 0.000 claims 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 claims 1
- 238000006297 dehydration reaction Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 159
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 141
- 239000000203 mixture Substances 0.000 description 122
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 103
- 101150041968 CDC13 gene Proteins 0.000 description 79
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 79
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 66
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 62
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
- 239000002904 solvent Substances 0.000 description 53
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 46
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 45
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 38
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- 239000000243 solution Substances 0.000 description 36
- 239000013078 crystal Substances 0.000 description 35
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 32
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 31
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 24
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 24
- 239000002253 acid Substances 0.000 description 23
- 238000004440 column chromatography Methods 0.000 description 23
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 22
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 22
- 239000000741 silica gel Substances 0.000 description 22
- 229910002027 silica gel Inorganic materials 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 20
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 19
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 19
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 230000002411 adverse Effects 0.000 description 18
- KOPFEFZSAMLEHK-UHFFFAOYSA-N 1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1C=CNN=1 KOPFEFZSAMLEHK-UHFFFAOYSA-N 0.000 description 16
- 235000011054 acetic acid Nutrition 0.000 description 15
- YMJLEPMVGQBLHL-UHFFFAOYSA-N 1h-pyrazole-5-carbonitrile Chemical compound N#CC1=CC=NN1 YMJLEPMVGQBLHL-UHFFFAOYSA-N 0.000 description 14
- 238000010438 heat treatment Methods 0.000 description 14
- 239000003960 organic solvent Substances 0.000 description 14
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 13
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 13
- 239000000706 filtrate Substances 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 12
- 239000003054 catalyst Substances 0.000 description 12
- 238000001816 cooling Methods 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 12
- 229910052783 alkali metal Inorganic materials 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000010792 warming Methods 0.000 description 11
- BNYCHCAYYYRJSH-UHFFFAOYSA-N 1h-pyrazole-5-carboxamide Chemical compound NC(=O)C1=CC=NN1 BNYCHCAYYYRJSH-UHFFFAOYSA-N 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 239000003638 chemical reducing agent Substances 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- 238000006722 reduction reaction Methods 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 9
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 229910052697 platinum Inorganic materials 0.000 description 8
- 150000003217 pyrazoles Chemical class 0.000 description 8
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 description 7
- 150000007524 organic acids Chemical class 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- 229910017052 cobalt Inorganic materials 0.000 description 6
- 239000010941 cobalt Substances 0.000 description 6
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 6
- 229910052802 copper Inorganic materials 0.000 description 6
- 239000010949 copper Substances 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 150000002148 esters Chemical group 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 6
- 150000007522 mineralic acids Chemical class 0.000 description 6
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 6
- 229910052763 palladium Inorganic materials 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- FEKUXLUOKFSMRO-UHFFFAOYSA-N (4-fluorophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=C(F)C=C1 FEKUXLUOKFSMRO-UHFFFAOYSA-N 0.000 description 5
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 5
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 5
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 5
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 150000008065 acid anhydrides Chemical class 0.000 description 5
- 239000002168 alkylating agent Substances 0.000 description 5
- 229940100198 alkylating agent Drugs 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 238000010531 catalytic reduction reaction Methods 0.000 description 5
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 5
- 125000004430 oxygen atom Chemical group O* 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 102000000503 Collagen Type II Human genes 0.000 description 4
- 108010041390 Collagen Type II Proteins 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- 208000007882 Gastritis Diseases 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 150000001342 alkaline earth metals Chemical class 0.000 description 4
- 150000003973 alkyl amines Chemical class 0.000 description 4
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 4
- 230000002785 anti-thrombosis Effects 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 210000000548 hind-foot Anatomy 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 4
- 235000010288 sodium nitrite Nutrition 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- KLBIUKJOZFWCLW-UHFFFAOYSA-N thallium(iii) nitrate Chemical compound [Tl+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O KLBIUKJOZFWCLW-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 3
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000012024 dehydrating agents Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 150000002391 heterocyclic compounds Chemical class 0.000 description 3
- 230000004968 inflammatory condition Effects 0.000 description 3
- 229910000765 intermetallic Inorganic materials 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 3
- TYWKFUDMIDTRSC-UHFFFAOYSA-N 1-(4-fluorophenyl)-5-(4-methylsulfanylphenyl)pyrazol-3-amine Chemical compound C1=CC(SC)=CC=C1C1=CC(N)=NN1C1=CC=C(F)C=C1 TYWKFUDMIDTRSC-UHFFFAOYSA-N 0.000 description 2
- JECUZQLBQKNEMW-UHFFFAOYSA-N 1-(4-methylsulfanylphenyl)ethanone Chemical compound CSC1=CC=C(C(C)=O)C=C1 JECUZQLBQKNEMW-UHFFFAOYSA-N 0.000 description 2
- JHTKOUJDEUQFOB-UHFFFAOYSA-N 1h-pyrazol-1-ium;chloride Chemical compound Cl.C=1C=NNC=1 JHTKOUJDEUQFOB-UHFFFAOYSA-N 0.000 description 2
- RGQWZRSRAZHQNF-UHFFFAOYSA-N 2-(4-fluorophenyl)-3-(4-methylsulfanylphenyl)-3,4-dihydropyrazol-5-amine Chemical compound C1=CC(SC)=CC=C1C1N(C=2C=CC(F)=CC=2)N=C(N)C1 RGQWZRSRAZHQNF-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 2
- CPBJUFSZBCMFHX-UHFFFAOYSA-N 3-(4-methylsulfanylphenyl)prop-2-enenitrile Chemical compound CSC1=CC=C(C=CC#N)C=C1 CPBJUFSZBCMFHX-UHFFFAOYSA-N 0.000 description 2
- OFFKXACAYBPTOW-UHFFFAOYSA-N 4-fluoro-1-(4-methylsulfanylphenyl)butane-1,3-dione Chemical compound CSC1=CC=C(C(=O)CC(=O)CF)C=C1 OFFKXACAYBPTOW-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- LFUHTXZIAVYRHL-UHFFFAOYSA-N 5-(4-fluorophenyl)-1-(4-methylsulfanylphenyl)pyrazole-3-carbonitrile Chemical compound C1=CC(SC)=CC=C1N1C(C=2C=CC(F)=CC=2)=CC(C#N)=N1 LFUHTXZIAVYRHL-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 208000035939 Alveolitis allergic Diseases 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000027496 Behcet disease Diseases 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000027932 Collagen disease Diseases 0.000 description 2
- 241000272201 Columbiformes Species 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 208000009386 Experimental Arthritis Diseases 0.000 description 2
- 208000027445 Farmer Lung Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 206010018634 Gouty Arthritis Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000011200 Kawasaki disease Diseases 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- 102000003820 Lipoxygenases Human genes 0.000 description 2
- 108090000128 Lipoxygenases Proteins 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- AZFNGPAYDKGCRB-XCPIVNJJSA-M [(1s,2s)-2-amino-1,2-diphenylethyl]-(4-methylphenyl)sulfonylazanide;chlororuthenium(1+);1-methyl-4-propan-2-ylbenzene Chemical compound [Ru+]Cl.CC(C)C1=CC=C(C)C=C1.C1=CC(C)=CC=C1S(=O)(=O)[N-][C@@H](C=1C=CC=CC=1)[C@@H](N)C1=CC=CC=C1 AZFNGPAYDKGCRB-XCPIVNJJSA-M 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 150000004982 aromatic amines Chemical class 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 208000020670 canker sore Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 2
- WYYQVWLEPYFFLP-UHFFFAOYSA-K chromium(3+);triacetate Chemical compound [Cr+3].CC([O-])=O.CC([O-])=O.CC([O-])=O WYYQVWLEPYFFLP-UHFFFAOYSA-K 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 2
- 229960003280 cupric chloride Drugs 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- NNJSDEORKBPVIH-UHFFFAOYSA-N ethyl 4-(4-formamidophenyl)-2,4-dioxobutanoate Chemical compound CCOC(=O)C(=O)CC(=O)C1=CC=C(NC=O)C=C1 NNJSDEORKBPVIH-UHFFFAOYSA-N 0.000 description 2
- VCXKJVDDPLFLDK-UHFFFAOYSA-N ethyl 4-(4-methylsulfanylphenyl)-2,4-dioxobutanoate Chemical compound CCOC(=O)C(=O)CC(=O)C1=CC=C(SC)C=C1 VCXKJVDDPLFLDK-UHFFFAOYSA-N 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 208000022195 farmer lung disease Diseases 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- CPQCSJYYDADLCZ-UHFFFAOYSA-N n-methylhydroxylamine Chemical compound CNO CPQCSJYYDADLCZ-UHFFFAOYSA-N 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 229910000480 nickel oxide Inorganic materials 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- GNRSAWUEBMWBQH-UHFFFAOYSA-N oxonickel Chemical compound [Ni]=O GNRSAWUEBMWBQH-UHFFFAOYSA-N 0.000 description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- 229910003445 palladium oxide Inorganic materials 0.000 description 2
- JQPTYAILLJKUCY-UHFFFAOYSA-N palladium(ii) oxide Chemical compound [O-2].[Pd+2] JQPTYAILLJKUCY-UHFFFAOYSA-N 0.000 description 2
- DPBLXKKOBLCELK-UHFFFAOYSA-N pentan-1-amine Chemical compound CCCCCN DPBLXKKOBLCELK-UHFFFAOYSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229910003446 platinum oxide Inorganic materials 0.000 description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 description 2
- 208000005987 polymyositis Diseases 0.000 description 2
- 239000004304 potassium nitrite Substances 0.000 description 2
- 235000010289 potassium nitrite Nutrition 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 239000012414 tert-butyl nitrite Substances 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 206010043778 thyroiditis Diseases 0.000 description 2
- 229910052718 tin Inorganic materials 0.000 description 2
- 239000011135 tin Substances 0.000 description 2
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 230000005951 type IV hypersensitivity Effects 0.000 description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- FROAJKIDLCONAY-UHFFFAOYSA-N (4-fluoro-2-nitrophenyl)hydrazine;hydrochloride Chemical compound Cl.NNC1=CC=C(F)C=C1[N+]([O-])=O FROAJKIDLCONAY-UHFFFAOYSA-N 0.000 description 1
- VGRXAHXMIDCTNV-UHFFFAOYSA-N (6-chlorobenzotriazol-1-yl) 4-chlorobenzenesulfonate Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)ON1C2=CC(Cl)=CC=C2N=N1 VGRXAHXMIDCTNV-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- NSZCXQVWUNROEJ-UHFFFAOYSA-N 1,5-bis(4-methoxyphenyl)pyrazole-3-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1=CC(C#N)=NN1C1=CC=C(OC)C=C1 NSZCXQVWUNROEJ-UHFFFAOYSA-N 0.000 description 1
- IKFOCNGLTGKUER-UHFFFAOYSA-N 1,5-bis(4-methoxyphenyl)pyrazole-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=CC(C(N)=O)=NN1C1=CC=C(OC)C=C1 IKFOCNGLTGKUER-UHFFFAOYSA-N 0.000 description 1
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 1
- JNDFDSGLVKLWQI-UHFFFAOYSA-N 1-(2,4-difluorophenyl)-5-(4-methylsulfanylphenyl)pyrazole-3-carbonitrile Chemical compound C1=CC(SC)=CC=C1C1=CC(C#N)=NN1C1=CC=C(F)C=C1F JNDFDSGLVKLWQI-UHFFFAOYSA-N 0.000 description 1
- HFIBZRNAXBENSC-UHFFFAOYSA-N 1-(2,4-difluorophenyl)-5-(4-methylsulfanylphenyl)pyrazole-3-carboxylic acid Chemical compound C1=CC(SC)=CC=C1C1=CC(C(O)=O)=NN1C1=CC=C(F)C=C1F HFIBZRNAXBENSC-UHFFFAOYSA-N 0.000 description 1
- QNISCHVBZFQXQG-UHFFFAOYSA-N 1-(2,4-difluorophenyl)-5-(4-methylsulfonylphenyl)pyrazole-3-carbonitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C#N)=NN1C1=CC=C(F)C=C1F QNISCHVBZFQXQG-UHFFFAOYSA-N 0.000 description 1
- ZCWIZDDVUNGPNU-UHFFFAOYSA-N 1-(2,5-difluorophenyl)-5-(4-methylsulfonylphenyl)pyrazole-3-carbonitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C#N)=NN1C1=CC(F)=CC=C1F ZCWIZDDVUNGPNU-UHFFFAOYSA-N 0.000 description 1
- ZXDJCRKJQDRRQJ-UHFFFAOYSA-N 1-(2-aminophenyl)-5-(4-methylsulfonylphenyl)pyrazole-3-carbonitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C#N)=NN1C1=CC=CC=C1N ZXDJCRKJQDRRQJ-UHFFFAOYSA-N 0.000 description 1
- VIMUSZVTDYLANX-UHFFFAOYSA-N 1-(2-chlorophenyl)-5-(4-methylsulfanylphenyl)pyrazole-3-carbonitrile Chemical compound C1=CC(SC)=CC=C1C1=CC(C#N)=NN1C1=CC=CC=C1Cl VIMUSZVTDYLANX-UHFFFAOYSA-N 0.000 description 1
- KWLXGTKMYOWMJL-UHFFFAOYSA-N 1-(2-chlorophenyl)-5-(4-methylsulfanylphenyl)pyrazole-3-carboxamide Chemical compound C1=CC(SC)=CC=C1C1=CC(C(N)=O)=NN1C1=CC=CC=C1Cl KWLXGTKMYOWMJL-UHFFFAOYSA-N 0.000 description 1
- CJAONDQLHGOLCP-UHFFFAOYSA-N 1-(2-fluorophenyl)-5-(4-methylsulfonylphenyl)pyrazole-3-carbonitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C#N)=NN1C1=CC=CC=C1F CJAONDQLHGOLCP-UHFFFAOYSA-N 0.000 description 1
- AAFYBCWFSJQLPX-UHFFFAOYSA-N 1-(3-fluorophenyl)-5-(4-methylsulfonylphenyl)pyrazole-3-carbonitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C#N)=NN1C1=CC=CC(F)=C1 AAFYBCWFSJQLPX-UHFFFAOYSA-N 0.000 description 1
- HTGILKJHDVTAOR-UHFFFAOYSA-N 1-(3-fluorophenyl)-5-(4-methylsulfonylphenyl)pyrazole-3-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C(N)=O)=NN1C1=CC=CC(F)=C1 HTGILKJHDVTAOR-UHFFFAOYSA-N 0.000 description 1
- NRJQRPBJJYSMPN-UHFFFAOYSA-N 1-(4-aminophenyl)-5-(5-methylsulfonylthiophen-2-yl)pyrazole-3-carbonitrile Chemical compound S1C(S(=O)(=O)C)=CC=C1C1=CC(C#N)=NN1C1=CC=C(N)C=C1 NRJQRPBJJYSMPN-UHFFFAOYSA-N 0.000 description 1
- SAQYYFCZIRZHDM-UHFFFAOYSA-N 1-(4-fluoro-2-nitrophenyl)-5-(4-methylsulfanylphenyl)pyrazole-3-carbonitrile Chemical compound C1=CC(SC)=CC=C1C1=CC(C#N)=NN1C1=CC=C(F)C=C1[N+]([O-])=O SAQYYFCZIRZHDM-UHFFFAOYSA-N 0.000 description 1
- WQIAMHYCPHRBJA-UHFFFAOYSA-N 1-(4-fluoro-2-nitrophenyl)-5-(4-methylsulfanylphenyl)pyrazole-3-carboxamide Chemical compound C1=CC(SC)=CC=C1C1=CC(C(N)=O)=NN1C1=CC=C(F)C=C1[N+]([O-])=O WQIAMHYCPHRBJA-UHFFFAOYSA-N 0.000 description 1
- MODSOARKOXFOHI-UHFFFAOYSA-N 1-(4-fluorophenyl)-5-(4-methoxyphenyl)pyrazole-3-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1=CC(C#N)=NN1C1=CC=C(F)C=C1 MODSOARKOXFOHI-UHFFFAOYSA-N 0.000 description 1
- RJOGTMRIXDONDI-UHFFFAOYSA-N 1-(4-fluorophenyl)-5-(4-methylphenyl)pyrazole-3-carboxamide Chemical compound C1=CC(C)=CC=C1C1=CC(C(N)=O)=NN1C1=CC=C(F)C=C1 RJOGTMRIXDONDI-UHFFFAOYSA-N 0.000 description 1
- XQYOBPMMXCTKEN-UHFFFAOYSA-N 1-(4-fluorophenyl)-5-(4-methylsulfanylphenyl)pyrazole-3-carbonitrile Chemical compound C1=CC(SC)=CC=C1C1=CC(C#N)=NN1C1=CC=C(F)C=C1 XQYOBPMMXCTKEN-UHFFFAOYSA-N 0.000 description 1
- JBXLGRLORITUHD-UHFFFAOYSA-N 1-(4-fluorophenyl)-5-(4-methylsulfanylphenyl)pyrazole-3-carboxylic acid Chemical compound C1=CC(SC)=CC=C1C1=CC(C(O)=O)=NN1C1=CC=C(F)C=C1 JBXLGRLORITUHD-UHFFFAOYSA-N 0.000 description 1
- VIANNBGWOVWXJL-UHFFFAOYSA-N 1-(4-fluorophenyl)-5-(4-methylsulfanylphenyl)pyrazole-4-carbonitrile Chemical compound C1=CC(SC)=CC=C1C1=C(C#N)C=NN1C1=CC=C(F)C=C1 VIANNBGWOVWXJL-UHFFFAOYSA-N 0.000 description 1
- NXRZFFXTDRGUKU-UHFFFAOYSA-N 1-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-n-phenylpyrazole-3-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C(=O)NC=2C=CC=CC=2)=NN1C1=CC=C(F)C=C1 NXRZFFXTDRGUKU-UHFFFAOYSA-N 0.000 description 1
- QWQDUBANGZTBRU-UHFFFAOYSA-N 1-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)pyrazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC=NN1C1=CC=C(F)C=C1 QWQDUBANGZTBRU-UHFFFAOYSA-N 0.000 description 1
- GAZFKNATWGWXFJ-UHFFFAOYSA-N 1-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)pyrazole-3-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C(N)=O)=NN1C1=CC=C(F)C=C1 GAZFKNATWGWXFJ-UHFFFAOYSA-N 0.000 description 1
- ICYAZXZMPHTVIL-UHFFFAOYSA-N 1-(4-fluorophenyl)-5-[4-(2-oxoethylamino)phenyl]pyrazole-3-carbonitrile Chemical compound C1=CC(F)=CC=C1N1C(C=2C=CC(NCC=O)=CC=2)=CC(C#N)=N1 ICYAZXZMPHTVIL-UHFFFAOYSA-N 0.000 description 1
- YZUJTGCNTFRMAV-UHFFFAOYSA-N 1-(4-fluorophenyl)-5-[4-(methylamino)phenyl]pyrazole-3-carbonitrile;hydrochloride Chemical compound Cl.C1=CC(NC)=CC=C1C1=CC(C#N)=NN1C1=CC=C(F)C=C1 YZUJTGCNTFRMAV-UHFFFAOYSA-N 0.000 description 1
- SZVBDWZQCRPEQO-UHFFFAOYSA-N 1-(4-fluorophenyl)-n,n-dimethyl-5-(4-methylsulfanylphenyl)pyrazole-3-carboxamide Chemical compound C1=CC(SC)=CC=C1C1=CC(C(=O)N(C)C)=NN1C1=CC=C(F)C=C1 SZVBDWZQCRPEQO-UHFFFAOYSA-N 0.000 description 1
- SNXJXBJONUDITL-UHFFFAOYSA-N 1-(4-fluorophenyl)-n,n-dimethyl-5-(4-methylsulfonylphenyl)pyrazole-3-carboxamide Chemical compound C=1C=C(F)C=CC=1N1N=C(C(=O)N(C)C)C=C1C1=CC=C(S(C)(=O)=O)C=C1 SNXJXBJONUDITL-UHFFFAOYSA-N 0.000 description 1
- YSKBLJWXWMBLRZ-UHFFFAOYSA-N 1-(4-fluorophenyl)-n-hydroxy-n-methyl-5-(4-methylsulfonylphenyl)pyrazole-3-carboxamide Chemical compound C=1C=C(F)C=CC=1N1N=C(C(=O)N(O)C)C=C1C1=CC=C(S(C)(=O)=O)C=C1 YSKBLJWXWMBLRZ-UHFFFAOYSA-N 0.000 description 1
- OKVYEQHCQICYPC-UHFFFAOYSA-N 1-(4-fluorophenyl)-n-methyl-5-(4-methylsulfonylphenyl)pyrazole-3-carboxamide Chemical compound C=1C=C(F)C=CC=1N1N=C(C(=O)NC)C=C1C1=CC=C(S(C)(=O)=O)C=C1 OKVYEQHCQICYPC-UHFFFAOYSA-N 0.000 description 1
- FZDQLIVLUUUSHS-UHFFFAOYSA-N 1-(4-hydroxyphenyl)-5-(4-methylsulfonylphenyl)pyrazole-3-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C(N)=O)=NN1C1=CC=C(O)C=C1 FZDQLIVLUUUSHS-UHFFFAOYSA-N 0.000 description 1
- AARAPTARSOZVKG-UHFFFAOYSA-N 1-(4-methoxyphenyl)-5-(4-methylsulfonylphenyl)pyrazole-3-carbonitrile Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(=CC=2)S(C)(=O)=O)=CC(C#N)=N1 AARAPTARSOZVKG-UHFFFAOYSA-N 0.000 description 1
- RIJLVJZZBDRPAQ-UHFFFAOYSA-N 1-(4-methoxyphenyl)-5-(4-methylsulfonylphenyl)pyrazole-3-carboxylic acid Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(=CC=2)S(C)(=O)=O)=CC(C(O)=O)=N1 RIJLVJZZBDRPAQ-UHFFFAOYSA-N 0.000 description 1
- BOINDPWDANNVKH-UHFFFAOYSA-N 1-(4-methylphenyl)-5-(4-methylsulfonylphenyl)pyrazole-3-carbonitrile Chemical compound C1=CC(C)=CC=C1N1C(C=2C=CC(=CC=2)S(C)(=O)=O)=CC(C#N)=N1 BOINDPWDANNVKH-UHFFFAOYSA-N 0.000 description 1
- UUTORDYTRTWXHJ-UHFFFAOYSA-N 1-(4-methylphenyl)-5-(4-methylsulfonylphenyl)pyrazole-3-carboxamide Chemical compound C1=CC(C)=CC=C1N1C(C=2C=CC(=CC=2)S(C)(=O)=O)=CC(C(N)=O)=N1 UUTORDYTRTWXHJ-UHFFFAOYSA-N 0.000 description 1
- CBHIVURENHBEFE-UHFFFAOYSA-N 1-(4-methylphenyl)-5-(4-methylsulfonylphenyl)pyrazole-3-carboxylic acid Chemical compound C1=CC(C)=CC=C1N1C(C=2C=CC(=CC=2)S(C)(=O)=O)=CC(C(O)=O)=N1 CBHIVURENHBEFE-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- YXXSEKAYDYCXER-UHFFFAOYSA-N 1-[1-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)pyrazol-3-yl]-2-methoxyethanone Chemical compound C=1C=C(F)C=CC=1N1N=C(C(=O)COC)C=C1C1=CC=C(S(C)(=O)=O)C=C1 YXXSEKAYDYCXER-UHFFFAOYSA-N 0.000 description 1
- CSROPHGEZWWLRG-UHFFFAOYSA-N 1-[1-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)pyrazol-3-yl]ethanone Chemical compound C=1C=C(F)C=CC=1N1N=C(C(=O)C)C=C1C1=CC=C(S(C)(=O)=O)C=C1 CSROPHGEZWWLRG-UHFFFAOYSA-N 0.000 description 1
- RMYZVXVHABKPIG-UHFFFAOYSA-N 1-[2-(dimethylamino)-4-fluorophenyl]-5-(4-methylsulfonylphenyl)pyrazole-3-carbonitrile Chemical compound CN(C)C1=CC(F)=CC=C1N1C(C=2C=CC(=CC=2)S(C)(=O)=O)=CC(C#N)=N1 RMYZVXVHABKPIG-UHFFFAOYSA-N 0.000 description 1
- OIZBULNXBBRYFR-UHFFFAOYSA-N 1-[4-(dimethylamino)phenyl]-5-(5-methylsulfonylthiophen-2-yl)pyrazole-3-carbonitrile Chemical compound C1=CC(N(C)C)=CC=C1N1C(C=2SC(=CC=2)S(C)(=O)=O)=CC(C#N)=N1 OIZBULNXBBRYFR-UHFFFAOYSA-N 0.000 description 1
- CTCVHBQKCDDASK-UHFFFAOYSA-N 1-[4-(ethylamino)phenyl]-5-(4-methylsulfonylphenyl)pyrazole-3-carbonitrile Chemical compound C1=CC(NCC)=CC=C1N1C(C=2C=CC(=CC=2)S(C)(=O)=O)=CC(C#N)=N1 CTCVHBQKCDDASK-UHFFFAOYSA-N 0.000 description 1
- RCBCXOWHMTZRQH-UHFFFAOYSA-N 1-[4-(methylamino)phenyl]-5-(4-methylphenyl)pyrazole-3-carbonitrile;hydrochloride Chemical compound Cl.C1=CC(NC)=CC=C1N1C(C=2C=CC(C)=CC=2)=CC(C#N)=N1 RCBCXOWHMTZRQH-UHFFFAOYSA-N 0.000 description 1
- AAEWURJFDCFLQM-UHFFFAOYSA-N 1-[4-(methylamino)phenyl]-5-(4-methylsulfinylphenyl)pyrazole-3-carbonitrile;hydrochloride Chemical compound Cl.C1=CC(NC)=CC=C1N1C(C=2C=CC(=CC=2)S(C)=O)=CC(C#N)=N1 AAEWURJFDCFLQM-UHFFFAOYSA-N 0.000 description 1
- VWJDPHUFKPDZRR-UHFFFAOYSA-N 1-[4-(methylamino)phenyl]-5-(4-methylsulfonylphenyl)pyrazole-3-carbonitrile Chemical compound C1=CC(NC)=CC=C1N1C(C=2C=CC(=CC=2)S(C)(=O)=O)=CC(C#N)=N1 VWJDPHUFKPDZRR-UHFFFAOYSA-N 0.000 description 1
- GYSKDBALPZNTOA-UHFFFAOYSA-N 1-[4-(methylamino)phenyl]-5-(4-methylsulfonylphenyl)pyrazole-3-carbonitrile;hydrochloride Chemical compound Cl.C1=CC(NC)=CC=C1N1C(C=2C=CC(=CC=2)S(C)(=O)=O)=CC(C#N)=N1 GYSKDBALPZNTOA-UHFFFAOYSA-N 0.000 description 1
- LKCSVYNJZYTVGP-UHFFFAOYSA-N 1-[4-(methylamino)phenyl]-5-(4-methylsulfonylphenyl)pyrazole-3-carboxamide Chemical compound C1=CC(NC)=CC=C1N1C(C=2C=CC(=CC=2)S(C)(=O)=O)=CC(C(N)=O)=N1 LKCSVYNJZYTVGP-UHFFFAOYSA-N 0.000 description 1
- RRVAFVRZZLELKA-UHFFFAOYSA-N 1-[4-(methylamino)phenyl]-5-(4-methylsulfonylphenyl)pyrazole-3-carboxylic acid Chemical compound C1=CC(NC)=CC=C1N1C(C=2C=CC(=CC=2)S(C)(=O)=O)=CC(C(O)=O)=N1 RRVAFVRZZLELKA-UHFFFAOYSA-N 0.000 description 1
- XRWOOFIMDZOPTC-UHFFFAOYSA-N 1-[4-(methylamino)phenyl]-5-(5-methylsulfonylthiophen-2-yl)pyrazole-3-carbonitrile;hydrochloride Chemical compound Cl.C1=CC(NC)=CC=C1N1C(C=2SC(=CC=2)S(C)(=O)=O)=CC(C#N)=N1 XRWOOFIMDZOPTC-UHFFFAOYSA-N 0.000 description 1
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- RUFPHBVGCFYCNW-UHFFFAOYSA-N 1-naphthylamine Chemical compound C1=CC=C2C(N)=CC=CC2=C1 RUFPHBVGCFYCNW-UHFFFAOYSA-N 0.000 description 1
- ZLIZZDCWMOGEGA-UHFFFAOYSA-N 1h-pyrazole-5-carbonyl chloride Chemical compound ClC(=O)C=1C=CNN=1 ZLIZZDCWMOGEGA-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
- GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical compound NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- IQCPPELOOOHROA-UHFFFAOYSA-N 2-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)pyrazole-3-carbonitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=NN(C=2C=CC(F)=CC=2)C(C#N)=C1 IQCPPELOOOHROA-UHFFFAOYSA-N 0.000 description 1
- KRAMQLSHAWMXRJ-UHFFFAOYSA-N 2-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)pyrazole-3-carboxylic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=NN(C=2C=CC(F)=CC=2)C(C(O)=O)=C1 KRAMQLSHAWMXRJ-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
- FYELSNVLZVIGTI-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-5-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1CC)CC(=O)N1CC2=C(CC1)NN=N2 FYELSNVLZVIGTI-UHFFFAOYSA-N 0.000 description 1
- LLAVYRHRAACGNE-UHFFFAOYSA-N 2-[4-[3-(difluoromethyl)-5-(4-methylsulfanylphenyl)pyrazol-1-yl]anilino]acetaldehyde Chemical compound C1=CC(SC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(NCC=O)C=C1 LLAVYRHRAACGNE-UHFFFAOYSA-N 0.000 description 1
- NZJQYRHLIHFHKW-UHFFFAOYSA-N 2-[4-[3-methylsulfonyl-5-(4-methylsulfonylphenyl)pyrazol-1-yl]anilino]acetaldehyde Chemical compound C=1C=C(NCC=O)C=CC=1N1N=C(S(=O)(=O)C)C=C1C1=CC=C(S(C)(=O)=O)C=C1 NZJQYRHLIHFHKW-UHFFFAOYSA-N 0.000 description 1
- MOEXAKRPPDYYHF-UHFFFAOYSA-N 2-[4-[5-(4-methylsulfonylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]anilino]acetaldehyde Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(NCC=O)C=C1 MOEXAKRPPDYYHF-UHFFFAOYSA-N 0.000 description 1
- KWMBADTWRIGGGG-UHFFFAOYSA-N 2-diethoxyphosphorylacetonitrile Chemical compound CCOP(=O)(CC#N)OCC KWMBADTWRIGGGG-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- UWKDOGXLOUHUMV-UHFFFAOYSA-N 3,3-bis(methylsulfanyl)-1-(4-methylsulfanylphenyl)prop-2-en-1-one Chemical compound CSC(SC)=CC(=O)C1=CC=C(SC)C=C1 UWKDOGXLOUHUMV-UHFFFAOYSA-N 0.000 description 1
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 1
- STOJNQQVMLJKOV-UHFFFAOYSA-N 3-(chloromethyl)-1-(4-fluorophenyl)-5-(4-methylsulfanylphenyl)pyrazole Chemical compound C1=CC(SC)=CC=C1C1=CC(CCl)=NN1C1=CC=C(F)C=C1 STOJNQQVMLJKOV-UHFFFAOYSA-N 0.000 description 1
- MEIBHHXURYPUCW-UHFFFAOYSA-N 3-(chloromethyl)-1-(4-fluorophenyl)-5-(4-methylsulfinylphenyl)pyrazole Chemical compound C1=CC(S(=O)C)=CC=C1C1=CC(CCl)=NN1C1=CC=C(F)C=C1 MEIBHHXURYPUCW-UHFFFAOYSA-N 0.000 description 1
- PMCUMAOGSWZOCW-UHFFFAOYSA-N 3-(chloromethyl)-1-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)pyrazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(CCl)=NN1C1=CC=C(F)C=C1 PMCUMAOGSWZOCW-UHFFFAOYSA-N 0.000 description 1
- AJYMUQHWGPOEFM-UHFFFAOYSA-N 3-(difluoromethyl)-1-(4-fluorophenyl)-5-(4-methylsulfanylphenyl)pyrazole Chemical compound C1=CC(SC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(F)C=C1 AJYMUQHWGPOEFM-UHFFFAOYSA-N 0.000 description 1
- HZMIJYLTQPSULZ-UHFFFAOYSA-N 3-(difluoromethyl)-1-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)pyrazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(F)C=C1 HZMIJYLTQPSULZ-UHFFFAOYSA-N 0.000 description 1
- BRVNWIXYLPMKKU-UHFFFAOYSA-N 3-(difluoromethyl)-5-(4-methylsulfanylphenyl)-1-(4-nitrophenyl)pyrazole Chemical compound C1=CC(SC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C([N+]([O-])=O)C=C1 BRVNWIXYLPMKKU-UHFFFAOYSA-N 0.000 description 1
- NYTQRAVNLPESFV-UHFFFAOYSA-N 3-(fluoromethyl)-1-(4-fluorophenyl)-5-(4-methylsulfinylphenyl)pyrazole Chemical compound C1=CC(S(=O)C)=CC=C1C1=CC(CF)=NN1C1=CC=C(F)C=C1 NYTQRAVNLPESFV-UHFFFAOYSA-N 0.000 description 1
- NNBVLEZZLKZIMO-UHFFFAOYSA-N 3-(fluoromethyl)-1-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)pyrazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(CF)=NN1C1=CC=C(F)C=C1 NNBVLEZZLKZIMO-UHFFFAOYSA-N 0.000 description 1
- PDXADGOPTZGGKK-UHFFFAOYSA-N 3-(fluoromethyl)-5-(4-methylsulfonylphenyl)-1-(4-nitrophenyl)pyrazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(CF)=NN1C1=CC=C([N+]([O-])=O)C=C1 PDXADGOPTZGGKK-UHFFFAOYSA-N 0.000 description 1
- GTNIPAFGVUQOPH-UHFFFAOYSA-N 3-bromo-1-(4-fluorophenyl)-5-(4-methylsulfanylphenyl)pyrazole Chemical compound C1=CC(SC)=CC=C1C1=CC(Br)=NN1C1=CC=C(F)C=C1 GTNIPAFGVUQOPH-UHFFFAOYSA-N 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- FHCHPEVTQKUOGG-UHFFFAOYSA-N 3-methylsulfanyl-5-(4-methylsulfanylphenyl)-1-(4-nitrophenyl)pyrazole Chemical compound C=1C=C([N+]([O-])=O)C=CC=1N1N=C(SC)C=C1C1=CC=C(SC)C=C1 FHCHPEVTQKUOGG-UHFFFAOYSA-N 0.000 description 1
- CLEVXKOUHZZSPT-UHFFFAOYSA-N 3-methylsulfonyl-5-(4-methylsulfonylphenyl)-1-(4-nitrophenyl)pyrazole Chemical compound C=1C=C([N+]([O-])=O)C=CC=1N1N=C(S(=O)(=O)C)C=C1C1=CC=C(S(C)(=O)=O)C=C1 CLEVXKOUHZZSPT-UHFFFAOYSA-N 0.000 description 1
- KJKMEWQBGDCXEF-UHFFFAOYSA-N 4,4,4-trifluoro-1-(4-methylsulfanylphenyl)butane-1,3-dione Chemical compound CSC1=CC=C(C(=O)CC(=O)C(F)(F)F)C=C1 KJKMEWQBGDCXEF-UHFFFAOYSA-N 0.000 description 1
- PGLOGEREYUWGFC-UHFFFAOYSA-N 4,4-difluoro-1-(4-methylsulfanylphenyl)butane-1,3-dione Chemical compound CSC1=CC=C(C(=O)CC(=O)C(F)F)C=C1 PGLOGEREYUWGFC-UHFFFAOYSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- KAWXGRXTFFOFQS-UHFFFAOYSA-N 4-[3-(fluoromethyl)-5-(4-methylsulfonylphenyl)pyrazol-1-yl]-n-methylaniline Chemical compound C1=CC(NC)=CC=C1N1C(C=2C=CC(=CC=2)S(C)(=O)=O)=CC(CF)=N1 KAWXGRXTFFOFQS-UHFFFAOYSA-N 0.000 description 1
- IJWIGNZZRWHKAP-UHFFFAOYSA-N 4-[5-(4-methylsulfinylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]aniline Chemical compound C1=CC(S(=O)C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(N)C=C1 IJWIGNZZRWHKAP-UHFFFAOYSA-N 0.000 description 1
- HFSDTTZSOYPCBP-UHFFFAOYSA-N 4-[5-(4-methylsulfonylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]aniline Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(N)C=C1 HFSDTTZSOYPCBP-UHFFFAOYSA-N 0.000 description 1
- TZLYLFFLMYTMRY-UHFFFAOYSA-N 4-bromo-1-(4-fluorophenyl)-5-(4-methylsulfanylphenyl)pyrazole Chemical compound C1=CC(SC)=CC=C1C1=C(Br)C=NN1C1=CC=C(F)C=C1 TZLYLFFLMYTMRY-UHFFFAOYSA-N 0.000 description 1
- PUGDHSSOXPHLPT-UHFFFAOYSA-N 4-fluoro-2-nitroaniline Chemical compound NC1=CC=C(F)C=C1[N+]([O-])=O PUGDHSSOXPHLPT-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- QRVYABWJVXXOTN-UHFFFAOYSA-N 4-methylsulfanylbenzaldehyde Chemical compound CSC1=CC=C(C=O)C=C1 QRVYABWJVXXOTN-UHFFFAOYSA-N 0.000 description 1
- SZOLNPZAGXIOAU-UHFFFAOYSA-N 5-(3,5-ditert-butyl-4-hydroxyphenyl)-1-(4-fluorophenyl)pyrazole-3-carboxylic acid Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C=2N(N=C(C=2)C(O)=O)C=2C=CC(F)=CC=2)=C1 SZOLNPZAGXIOAU-UHFFFAOYSA-N 0.000 description 1
- FPSUIRQLPAKNHT-UHFFFAOYSA-N 5-(4-acetamidophenyl)-1-(4-fluorophenyl)pyrazole-3-carboxamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=CC(C(N)=O)=NN1C1=CC=C(F)C=C1 FPSUIRQLPAKNHT-UHFFFAOYSA-N 0.000 description 1
- GRXNBYGLHHAWKZ-UHFFFAOYSA-N 5-(4-aminophenyl)-1-(4-fluorophenyl)pyrazole-3-carboxamide Chemical compound C=1C=C(F)C=CC=1N1N=C(C(=O)N)C=C1C1=CC=C(N)C=C1 GRXNBYGLHHAWKZ-UHFFFAOYSA-N 0.000 description 1
- QBTDMZJQWZDCIA-UHFFFAOYSA-N 5-(4-cyanophenyl)-1-(4-fluorophenyl)pyrazole-3-carbonitrile Chemical compound C1=CC(F)=CC=C1N1C(C=2C=CC(=CC=2)C#N)=CC(C#N)=N1 QBTDMZJQWZDCIA-UHFFFAOYSA-N 0.000 description 1
- YYLUGDPUQPRMHF-UHFFFAOYSA-N 5-(4-cyanophenyl)-1-(4-fluorophenyl)pyrazole-3-carboxamide Chemical compound C=1C=C(F)C=CC=1N1N=C(C(=O)N)C=C1C1=CC=C(C#N)C=C1 YYLUGDPUQPRMHF-UHFFFAOYSA-N 0.000 description 1
- HFIZRLRRIFKDKO-UHFFFAOYSA-N 5-(4-fluorophenyl)-1-(4-methylsulfanylphenyl)pyrazole-3-carboxylic acid Chemical compound C1=CC(SC)=CC=C1N1C(C=2C=CC(F)=CC=2)=CC(C(O)=O)=N1 HFIZRLRRIFKDKO-UHFFFAOYSA-N 0.000 description 1
- BHLDRHUGYPYBQM-UHFFFAOYSA-N 5-(4-methoxyphenyl)-1-(4-nitrophenyl)pyrazole-3-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1=CC(C#N)=NN1C1=CC=C([N+]([O-])=O)C=C1 BHLDRHUGYPYBQM-UHFFFAOYSA-N 0.000 description 1
- UCPVWVLWUAERGC-UHFFFAOYSA-N 5-(4-methoxyphenyl)-1-[4-(2-oxoethylamino)phenyl]pyrazole-3-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1=CC(C#N)=NN1C1=CC=C(NCC=O)C=C1 UCPVWVLWUAERGC-UHFFFAOYSA-N 0.000 description 1
- VXZAUMDYLYONGG-UHFFFAOYSA-N 5-(4-methylphenyl)-1-[4-(2-oxoethylamino)phenyl]pyrazole-3-carbonitrile Chemical compound C1=CC(C)=CC=C1C1=CC(C#N)=NN1C1=CC=C(NCC=O)C=C1 VXZAUMDYLYONGG-UHFFFAOYSA-N 0.000 description 1
- NMUFZNAKWRXGRU-UHFFFAOYSA-N 5-(4-methylsulfanylphenyl)-1-(2-nitrophenyl)pyrazole-3-carbonitrile Chemical compound C1=CC(SC)=CC=C1C1=CC(C#N)=NN1C1=CC=CC=C1[N+]([O-])=O NMUFZNAKWRXGRU-UHFFFAOYSA-N 0.000 description 1
- BQFJXFXVFIELTN-UHFFFAOYSA-N 5-(4-methylsulfanylphenyl)-1-(4-nitrophenyl)pyrazole-3-carbonitrile Chemical compound C1=CC(SC)=CC=C1C1=CC(C#N)=NN1C1=CC=C([N+]([O-])=O)C=C1 BQFJXFXVFIELTN-UHFFFAOYSA-N 0.000 description 1
- ZWNNLUPQUVRZAQ-UHFFFAOYSA-N 5-(4-methylsulfanylphenyl)-1-(4-nitrophenyl)pyrazole-3-carboxylic acid Chemical compound C1=CC(SC)=CC=C1C1=CC(C(O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 ZWNNLUPQUVRZAQ-UHFFFAOYSA-N 0.000 description 1
- QYEMDMNZWTTXRT-UHFFFAOYSA-N 5-(4-methylsulfanylphenyl)-1-[4-(2-oxoethylamino)phenyl]pyrazole-3-carbonitrile Chemical compound C1=CC(SC)=CC=C1C1=CC(C#N)=NN1C1=CC=C(NCC=O)C=C1 QYEMDMNZWTTXRT-UHFFFAOYSA-N 0.000 description 1
- ULKWMOKMZZEKLC-UHFFFAOYSA-N 5-(4-methylsulfanylphenyl)-1-[4-(2-oxoethylamino)phenyl]pyrazole-3-carboxamide Chemical compound C1=CC(SC)=CC=C1C1=CC(C(N)=O)=NN1C1=CC=C(NCC=O)C=C1 ULKWMOKMZZEKLC-UHFFFAOYSA-N 0.000 description 1
- LYPOOYFPLRAIDW-UHFFFAOYSA-N 5-(4-methylsulfanylphenyl)-1-pyridin-4-ylpyrazole-3-carbonitrile;hydrochloride Chemical compound Cl.C1=CC(SC)=CC=C1C1=CC(C#N)=NN1C1=CC=NC=C1 LYPOOYFPLRAIDW-UHFFFAOYSA-N 0.000 description 1
- BAQXZXUKRUATFC-UHFFFAOYSA-N 5-(4-methylsulfanylphenyl)-1-pyridin-4-ylpyrazole-3-carboxamide Chemical compound C1=CC(SC)=CC=C1C1=CC(C(N)=O)=NN1C1=CC=NC=C1 BAQXZXUKRUATFC-UHFFFAOYSA-N 0.000 description 1
- GPIFUIAAKAIJRE-UHFFFAOYSA-N 5-(4-methylsulfonylphenyl)-1-(2-nitrophenyl)pyrazole-3-carbonitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C#N)=NN1C1=CC=CC=C1[N+]([O-])=O GPIFUIAAKAIJRE-UHFFFAOYSA-N 0.000 description 1
- IDZMDYOHDJOOIP-UHFFFAOYSA-N 5-(4-methylsulfonylphenyl)-1-(4-nitrophenyl)pyrazole-3-carbonitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C#N)=NN1C1=CC=C([N+]([O-])=O)C=C1 IDZMDYOHDJOOIP-UHFFFAOYSA-N 0.000 description 1
- XDQAQKGAAPHOFY-UHFFFAOYSA-N 5-(4-methylsulfonylphenyl)-1-[2-(2-oxoethylamino)phenyl]pyrazole-3-carbonitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C#N)=NN1C1=CC=CC=C1NCC=O XDQAQKGAAPHOFY-UHFFFAOYSA-N 0.000 description 1
- GJPHEQBYDGTNMH-UHFFFAOYSA-N 5-(4-methylsulfonylphenyl)-1-[4-(2-oxoethylamino)phenyl]pyrazole-3-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C(N)=O)=NN1C1=CC=C(NCC=O)C=C1 GJPHEQBYDGTNMH-UHFFFAOYSA-N 0.000 description 1
- XMUWAUIRNDIKRK-UHFFFAOYSA-N 5-(4-methylsulfonylphenyl)-1-[4-(2-oxoethylamino)phenyl]pyrazole-3-carboxylic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C(O)=O)=NN1C1=CC=C(NCC=O)C=C1 XMUWAUIRNDIKRK-UHFFFAOYSA-N 0.000 description 1
- TWMXWSDLKRQSCX-UHFFFAOYSA-N 5-(4-methylsulfonylphenyl)-1-phenylpyrazole-3-carboxylic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C(O)=O)=NN1C1=CC=CC=C1 TWMXWSDLKRQSCX-UHFFFAOYSA-N 0.000 description 1
- RHSRJYFJJBRGGU-UHFFFAOYSA-N 5-(4-methylsulfonylphenyl)-1-pyridin-4-ylpyrazole-3-carbonitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C#N)=NN1C1=CC=NC=C1 RHSRJYFJJBRGGU-UHFFFAOYSA-N 0.000 description 1
- KEQCEDLIGZDXNH-UHFFFAOYSA-N 5-(4-methylsulfonylphenyl)-1-pyridin-4-ylpyrazole-3-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C(N)=O)=NN1C1=CC=NC=C1 KEQCEDLIGZDXNH-UHFFFAOYSA-N 0.000 description 1
- RPQRKAZJVQVVRB-UHFFFAOYSA-N 5-(5-methylsulfanylthiophen-2-yl)-1-(4-nitrophenyl)pyrazole-3-carbonitrile Chemical compound S1C(SC)=CC=C1C1=CC(C#N)=NN1C1=CC=C([N+]([O-])=O)C=C1 RPQRKAZJVQVVRB-UHFFFAOYSA-N 0.000 description 1
- RMUZNZKATPJGAY-UHFFFAOYSA-N 5-(5-methylsulfanylthiophen-2-yl)-1-(4-nitrophenyl)pyrazole-3-carboxamide Chemical compound S1C(SC)=CC=C1C1=CC(C(N)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 RMUZNZKATPJGAY-UHFFFAOYSA-N 0.000 description 1
- SLBWODCXJJNDJS-UHFFFAOYSA-N 5-(5-methylsulfonylthiophen-2-yl)-1-(4-nitrophenyl)pyrazole-3-carbonitrile Chemical compound S1C(S(=O)(=O)C)=CC=C1C1=CC(C#N)=NN1C1=CC=C([N+]([O-])=O)C=C1 SLBWODCXJJNDJS-UHFFFAOYSA-N 0.000 description 1
- FFXVJFLKDIBWOW-UHFFFAOYSA-N 5-[1-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)pyrazol-3-yl]-2h-tetrazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C=2NN=NN=2)=NN1C1=CC=C(F)C=C1 FFXVJFLKDIBWOW-UHFFFAOYSA-N 0.000 description 1
- RVDLHGSZWAELAU-UHFFFAOYSA-N 5-tert-butylthiophene-2-carbonyl chloride Chemical compound CC(C)(C)C1=CC=C(C(Cl)=O)S1 RVDLHGSZWAELAU-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- GEHMBYLTCISYNY-UHFFFAOYSA-N Ammonium sulfamate Chemical compound [NH4+].NS([O-])(=O)=O GEHMBYLTCISYNY-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- ASMQGLCHMVWBQR-UHFFFAOYSA-N Diphenyl phosphate Chemical compound C=1C=CC=CC=1OP(=O)(O)OC1=CC=CC=C1 ASMQGLCHMVWBQR-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 239000003810 Jones reagent Substances 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- YIKSCQDJHCMVMK-UHFFFAOYSA-N Oxamide Chemical compound NC(=O)C(N)=O YIKSCQDJHCMVMK-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- FUUYAHJDPRONAN-UHFFFAOYSA-N [1-(4-fluorophenyl)-5-(4-methylsulfanylphenyl)pyrazol-3-yl]-pyrrolidin-1-ylmethanone Chemical compound C1=CC(SC)=CC=C1C1=CC(C(=O)N2CCCC2)=NN1C1=CC=C(F)C=C1 FUUYAHJDPRONAN-UHFFFAOYSA-N 0.000 description 1
- BIRQVHZQDSMVDV-UHFFFAOYSA-N [1-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)pyrazol-3-yl]-pyrrolidin-1-ylmethanone Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C(=O)N2CCCC2)=NN1C1=CC=C(F)C=C1 BIRQVHZQDSMVDV-UHFFFAOYSA-N 0.000 description 1
- QRXXOKQUDKQTAU-UHFFFAOYSA-N [4-[3-cyano-5-(4-methylsulfonylphenyl)pyrazol-1-yl]phenyl] methanesulfonate Chemical compound C1=CC(OS(=O)(=O)C)=CC=C1N1C(C=2C=CC(=CC=2)S(C)(=O)=O)=CC(C#N)=N1 QRXXOKQUDKQTAU-UHFFFAOYSA-N 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910001508 alkali metal halide Inorganic materials 0.000 description 1
- 150000008045 alkali metal halides Chemical class 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- FLLNLJJKHKZKMB-UHFFFAOYSA-N boron;tetramethylazanium Chemical compound [B].C[N+](C)(C)C FLLNLJJKHKZKMB-UHFFFAOYSA-N 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UETLMBWMVIQIGU-UHFFFAOYSA-N calcium azide Chemical compound [Ca+2].[N-]=[N+]=[N-].[N-]=[N+]=[N-] UETLMBWMVIQIGU-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 229940045803 cuprous chloride Drugs 0.000 description 1
- DBWFQCAODYUBGH-UHFFFAOYSA-N cyclobutanamine;cyclopentanamine Chemical compound NC1CCC1.NC1CCCC1 DBWFQCAODYUBGH-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- VQYIGTFOUJIDAQ-UHFFFAOYSA-N diethyl 2-[1-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)pyrazole-3-carbonyl]propanedioate Chemical compound C=1C=C(F)C=CC=1N1N=C(C(=O)C(C(=O)OCC)C(=O)OCC)C=C1C1=CC=C(S(C)(=O)=O)C=C1 VQYIGTFOUJIDAQ-UHFFFAOYSA-N 0.000 description 1
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000006264 diethylaminomethyl group Chemical group [H]C([H])([H])C([H])([H])N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000001 effect on platelet aggregation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- AIOKIAZWWNBJMD-UHFFFAOYSA-N ethyl 1,5-bis(4-methoxyphenyl)pyrazole-3-carboxylate Chemical compound C=1C=C(OC)C=CC=1N1N=C(C(=O)OCC)C=C1C1=CC=C(OC)C=C1 AIOKIAZWWNBJMD-UHFFFAOYSA-N 0.000 description 1
- RNNZKFBGFPFMGM-UHFFFAOYSA-N ethyl 1-(2,4-difluorophenyl)-5-(4-methylsulfanylphenyl)pyrazole-3-carboxylate Chemical compound C=1C=C(F)C=C(F)C=1N1N=C(C(=O)OCC)C=C1C1=CC=C(SC)C=C1 RNNZKFBGFPFMGM-UHFFFAOYSA-N 0.000 description 1
- BYXLBKNEGLQIFG-UHFFFAOYSA-N ethyl 1-(3-fluorophenyl)-5-(4-methylsulfonylphenyl)pyrazole-3-carboxylate Chemical compound C=1C=CC(F)=CC=1N1N=C(C(=O)OCC)C=C1C1=CC=C(S(C)(=O)=O)C=C1 BYXLBKNEGLQIFG-UHFFFAOYSA-N 0.000 description 1
- ZGHMZWHKHSVGCH-UHFFFAOYSA-N ethyl 1-(4-fluorophenyl)-5-(4-methylsulfanylphenyl)pyrazole-3-carboxylate Chemical compound C=1C=C(F)C=CC=1N1N=C(C(=O)OCC)C=C1C1=CC=C(SC)C=C1 ZGHMZWHKHSVGCH-UHFFFAOYSA-N 0.000 description 1
- XGNJUXREQVAIEN-UHFFFAOYSA-N ethyl 1-(4-fluorophenyl)-5-[4-(2-oxoethylamino)phenyl]pyrazole-3-carboxylate Chemical compound C=1C=C(F)C=CC=1N1N=C(C(=O)OCC)C=C1C1=CC=C(NCC=O)C=C1 XGNJUXREQVAIEN-UHFFFAOYSA-N 0.000 description 1
- WDGXVSGGGVZQKU-UHFFFAOYSA-N ethyl 1-(4-formamidophenyl)-5-(4-methylphenyl)pyrazole-3-carboxylate Chemical compound C=1C=C(NC=O)C=CC=1N1N=C(C(=O)OCC)C=C1C1=CC=C(C)C=C1 WDGXVSGGGVZQKU-UHFFFAOYSA-N 0.000 description 1
- JOFOJUNBRCBGHF-UHFFFAOYSA-N ethyl 1-(4-formamidophenyl)-5-(4-methylsulfanylphenyl)pyrazole-3-carboxylate Chemical compound C=1C=C(NC=O)C=CC=1N1N=C(C(=O)OCC)C=C1C1=CC=C(SC)C=C1 JOFOJUNBRCBGHF-UHFFFAOYSA-N 0.000 description 1
- ZQFYUPRRTJMTDX-UHFFFAOYSA-N ethyl 1-(4-methoxyphenyl)-5-(4-methylsulfonylphenyl)pyrazole-3-carboxylate Chemical compound C=1C=C(OC)C=CC=1N1N=C(C(=O)OCC)C=C1C1=CC=C(S(C)(=O)=O)C=C1 ZQFYUPRRTJMTDX-UHFFFAOYSA-N 0.000 description 1
- MZHWVKVPHTWDLG-UHFFFAOYSA-N ethyl 1-(4-methylphenyl)-5-(4-methylsulfonylphenyl)pyrazole-3-carboxylate Chemical compound C=1C=C(C)C=CC=1N1N=C(C(=O)OCC)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MZHWVKVPHTWDLG-UHFFFAOYSA-N 0.000 description 1
- GTFQWMDAUWOOKN-UHFFFAOYSA-N ethyl 4-(3,5-ditert-butyl-4-hydroxyphenyl)-2,4-dioxobutanoate Chemical compound CCOC(=O)C(=O)CC(=O)C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 GTFQWMDAUWOOKN-UHFFFAOYSA-N 0.000 description 1
- KHEAMBUFZSDFDX-UHFFFAOYSA-N ethyl 4-(4-acetylphenyl)-2,4-dioxobutanoate Chemical compound CCOC(=O)C(=O)CC(=O)C1=CC=C(C(C)=O)C=C1 KHEAMBUFZSDFDX-UHFFFAOYSA-N 0.000 description 1
- QQMYOPVSVNPECO-UHFFFAOYSA-N ethyl 4-(4-methylphenyl)-2,4-dioxobutanoate Chemical compound CCOC(=O)C(=O)CC(=O)C1=CC=C(C)C=C1 QQMYOPVSVNPECO-UHFFFAOYSA-N 0.000 description 1
- XWLRUMMFRQBZRJ-UHFFFAOYSA-N ethyl 4-(5-methylsulfanylthiophen-2-yl)-2,4-dioxobutanoate Chemical compound CCOC(=O)C(=O)CC(=O)C1=CC=C(SC)S1 XWLRUMMFRQBZRJ-UHFFFAOYSA-N 0.000 description 1
- LDWPVWOOEXIMHD-UHFFFAOYSA-N ethyl 5-(4-acetylphenyl)-1-(4-fluorophenyl)pyrazole-3-carboxylate Chemical compound C=1C=C(F)C=CC=1N1N=C(C(=O)OCC)C=C1C1=CC=C(C(C)=O)C=C1 LDWPVWOOEXIMHD-UHFFFAOYSA-N 0.000 description 1
- LZAKZEGXSFXNHG-UHFFFAOYSA-N ethyl 5-(4-cyanophenyl)-1-(4-fluorophenyl)pyrazole-3-carboxylate Chemical compound C=1C=C(F)C=CC=1N1N=C(C(=O)OCC)C=C1C1=CC=C(C#N)C=C1 LZAKZEGXSFXNHG-UHFFFAOYSA-N 0.000 description 1
- MIHJOENGEGDFRA-UHFFFAOYSA-N ethyl 5-(4-methoxyphenyl)-1-(4-nitrophenyl)pyrazole-3-carboxylate Chemical compound C=1C=C([N+]([O-])=O)C=CC=1N1N=C(C(=O)OCC)C=C1C1=CC=C(OC)C=C1 MIHJOENGEGDFRA-UHFFFAOYSA-N 0.000 description 1
- OPGLXDJBUNQJPT-UHFFFAOYSA-N ethyl 5-(4-methylphenyl)-1-(4-nitrophenyl)pyrazole-3-carboxylate Chemical compound C=1C=C([N+]([O-])=O)C=CC=1N1N=C(C(=O)OCC)C=C1C1=CC=C(C)C=C1 OPGLXDJBUNQJPT-UHFFFAOYSA-N 0.000 description 1
- WTMFFRPNRZBJCF-UHFFFAOYSA-N ethyl 5-(4-methylphenyl)-1-[4-(2-oxoethylamino)phenyl]pyrazole-3-carboxylate Chemical compound C=1C=C(NCC=O)C=CC=1N1N=C(C(=O)OCC)C=C1C1=CC=C(C)C=C1 WTMFFRPNRZBJCF-UHFFFAOYSA-N 0.000 description 1
- GHUBNPKEBHNMJO-UHFFFAOYSA-N ethyl 5-(4-methylsulfanylphenyl)-1-(2-nitrophenyl)pyrazole-3-carboxylate Chemical compound C=1C=CC=C([N+]([O-])=O)C=1N1N=C(C(=O)OCC)C=C1C1=CC=C(SC)C=C1 GHUBNPKEBHNMJO-UHFFFAOYSA-N 0.000 description 1
- ZAXSDFNRCWBQTI-UHFFFAOYSA-N ethyl 5-(4-methylsulfanylphenyl)-1-phenylpyrazole-3-carboxylate Chemical compound C=1C=CC=CC=1N1N=C(C(=O)OCC)C=C1C1=CC=C(SC)C=C1 ZAXSDFNRCWBQTI-UHFFFAOYSA-N 0.000 description 1
- CCMWYELBFYIUTB-UHFFFAOYSA-N ethyl 5-(4-methylsulfonylphenyl)-1-pyridin-4-ylpyrazole-3-carboxylate Chemical compound C=1C=NC=CC=1N1N=C(C(=O)OCC)C=C1C1=CC=C(S(C)(=O)=O)C=C1 CCMWYELBFYIUTB-UHFFFAOYSA-N 0.000 description 1
- 125000006534 ethyl amino methyl group Chemical group [H]N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005935 hexyloxycarbonyl group Chemical group 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- JUINSXZKUKVTMD-UHFFFAOYSA-N hydrogen azide Chemical compound N=[N+]=[N-] JUINSXZKUKVTMD-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910003480 inorganic solid Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- CRGZYKWWYNQGEC-UHFFFAOYSA-N magnesium;methanolate Chemical compound [Mg+2].[O-]C.[O-]C CRGZYKWWYNQGEC-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- OQJWFSVVBUCFMZ-UHFFFAOYSA-N methyl n-[1-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)pyrazol-3-yl]carbamate Chemical compound C=1C=C(F)C=CC=1N1N=C(NC(=O)OC)C=C1C1=CC=C(S(C)(=O)=O)C=C1 OQJWFSVVBUCFMZ-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- QWYWYBJSXUWMDD-UHFFFAOYSA-N n,n-dimethyl-5-(4-methylsulfonylphenyl)-1-[4-(2-oxoethylamino)phenyl]pyrazole-3-carboxamide Chemical compound C=1C=C(NCC=O)C=CC=1N1N=C(C(=O)N(C)C)C=C1C1=CC=C(S(C)(=O)=O)C=C1 QWYWYBJSXUWMDD-UHFFFAOYSA-N 0.000 description 1
- VMESOKCXSYNAKD-UHFFFAOYSA-N n,n-dimethylhydroxylamine Chemical compound CN(C)O VMESOKCXSYNAKD-UHFFFAOYSA-N 0.000 description 1
- ZMWVJZFYSRGJGK-UHFFFAOYSA-N n-[2-[3-cyano-5-(4-methylsulfonylphenyl)pyrazol-1-yl]phenyl]formamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C#N)=NN1C1=CC=CC=C1NC=O ZMWVJZFYSRGJGK-UHFFFAOYSA-N 0.000 description 1
- XXNXBJHRXJOUQQ-UHFFFAOYSA-N n-[4-[3-cyano-5-(4-methoxyphenyl)pyrazol-1-yl]phenyl]formamide Chemical compound C1=CC(OC)=CC=C1C1=CC(C#N)=NN1C1=CC=C(NC=O)C=C1 XXNXBJHRXJOUQQ-UHFFFAOYSA-N 0.000 description 1
- BKILYJWAHQEAGM-UHFFFAOYSA-N n-[4-[3-cyano-5-(4-methylsulfonylphenyl)pyrazol-1-yl]phenyl]formamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C#N)=NN1C1=CC=C(NC=O)C=C1 BKILYJWAHQEAGM-UHFFFAOYSA-N 0.000 description 1
- YNOYTUDGMVQLNJ-UHFFFAOYSA-N n-[4-[3-cyano-5-(4-methylsulfonylphenyl)pyrazol-1-yl]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1N1C(C=2C=CC(=CC=2)S(C)(=O)=O)=CC(C#N)=N1 YNOYTUDGMVQLNJ-UHFFFAOYSA-N 0.000 description 1
- UDUPHVJKFGCLBS-UHFFFAOYSA-N n-[4-[5-(4-methylsulfanylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]formamide Chemical compound C1=CC(SC)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(NC=O)C=C1 UDUPHVJKFGCLBS-UHFFFAOYSA-N 0.000 description 1
- PVDPKOPOUALBSX-UHFFFAOYSA-N n-[4-[5-(4-methylsulfinylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]formamide Chemical compound C1=CC(S(=O)C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(NC=O)C=C1 PVDPKOPOUALBSX-UHFFFAOYSA-N 0.000 description 1
- MRPLJIYEXYMNBO-UHFFFAOYSA-N n-[4-[5-(4-methylsulfonylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]formamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(NC=O)C=C1 MRPLJIYEXYMNBO-UHFFFAOYSA-N 0.000 description 1
- SAMQWYYFDXOTNY-UHFFFAOYSA-N n-[[1-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)pyrazol-3-yl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1N1N=C(CNC(=O)C)C=C1C1=CC=C(S(C)(=O)=O)C=C1 SAMQWYYFDXOTNY-UHFFFAOYSA-N 0.000 description 1
- SWTFBLUIBHXOAH-UHFFFAOYSA-N n-butylhydroxylamine Chemical compound CCCCNO SWTFBLUIBHXOAH-UHFFFAOYSA-N 0.000 description 1
- ZQMDPSKTPXNCAQ-UHFFFAOYSA-N n-cyclopropyl-1-(4-fluorophenyl)-5-(4-methylsulfanylphenyl)pyrazole-3-carboxamide Chemical compound C1=CC(SC)=CC=C1C1=CC(C(=O)NC2CC2)=NN1C1=CC=C(F)C=C1 ZQMDPSKTPXNCAQ-UHFFFAOYSA-N 0.000 description 1
- VDUIPQNXOQMTBF-UHFFFAOYSA-N n-ethylhydroxylamine Chemical compound CCNO VDUIPQNXOQMTBF-UHFFFAOYSA-N 0.000 description 1
- PXSXRABJBXYMFT-UHFFFAOYSA-N n-hexylhexan-1-amine Chemical compound CCCCCCNCCCCCC PXSXRABJBXYMFT-UHFFFAOYSA-N 0.000 description 1
- LQCVEYRPHXYHLO-UHFFFAOYSA-N n-methyl-4-[5-(4-methylsulfinylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]aniline;hydrochloride Chemical compound Cl.C1=CC(NC)=CC=C1N1C(C=2C=CC(=CC=2)S(C)=O)=CC(C(F)(F)F)=N1 LQCVEYRPHXYHLO-UHFFFAOYSA-N 0.000 description 1
- JACMPVXHEARCBO-UHFFFAOYSA-N n-pentylpentan-1-amine Chemical compound CCCCCNCCCCC JACMPVXHEARCBO-UHFFFAOYSA-N 0.000 description 1
- ODHYIQOBTIWVRZ-UHFFFAOYSA-N n-propan-2-ylhydroxylamine Chemical compound CC(C)NO ODHYIQOBTIWVRZ-UHFFFAOYSA-N 0.000 description 1
- OMXHKVKIKSASRV-UHFFFAOYSA-N n-propylhydroxylamine Chemical compound CCCNO OMXHKVKIKSASRV-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229940100684 pentylamine Drugs 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- TZLVRPLSVNESQC-UHFFFAOYSA-N potassium azide Chemical compound [K+].[N-]=[N+]=[N-] TZLVRPLSVNESQC-UHFFFAOYSA-N 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- XWVKTOHUMPLABF-UHFFFAOYSA-N thallium(3+) Chemical class [Tl+3] XWVKTOHUMPLABF-UHFFFAOYSA-N 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- RXJKFRMDXUJTEX-UHFFFAOYSA-N triethylphosphine Chemical compound CCP(CC)CC RXJKFRMDXUJTEX-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB898921466A GB8921466D0 (en) | 1989-09-22 | 1989-09-22 | Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same |
| GB909008399A GB9008399D0 (en) | 1990-04-12 | 1990-04-12 | Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL95675A0 IL95675A0 (en) | 1991-06-30 |
| IL95675A true IL95675A (en) | 1996-03-31 |
Family
ID=26295958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9567590A IL95675A (en) | 1989-09-22 | 1990-09-13 | N-aryl-pyrazole derivatives processes for their preparation and pharmaceutical compositions containing them |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5134142A (fr) |
| EP (1) | EP0418845B1 (fr) |
| JP (1) | JP2586713B2 (fr) |
| KR (1) | KR0182798B1 (fr) |
| CN (1) | CN1046506C (fr) |
| AT (1) | ATE126216T1 (fr) |
| AU (1) | AU637142B2 (fr) |
| CA (1) | CA2025599C (fr) |
| DE (1) | DE69021472T2 (fr) |
| DK (1) | DK0418845T3 (fr) |
| ES (1) | ES2088933T3 (fr) |
| FI (1) | FI102535B (fr) |
| GR (1) | GR3017100T3 (fr) |
| HU (2) | HU208122B (fr) |
| IE (1) | IE68857B1 (fr) |
| IL (1) | IL95675A (fr) |
| NO (1) | NO301006B1 (fr) |
| PH (1) | PH27357A (fr) |
| PT (1) | PT95389B (fr) |
| RU (2) | RU2021990C1 (fr) |
Families Citing this family (218)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU616564B2 (en) * | 1988-09-29 | 1991-10-31 | Sumitomo Chemical Company, Limited | Novel pyrazole compounds, method for production thereof, use thereof and intermediates for production thereof |
| DE4039733A1 (de) * | 1990-12-13 | 1992-06-17 | Basf Ag | Substituierte 5-aminopyrazole |
| NO179282C (no) * | 1991-01-18 | 1996-09-11 | Rhone Poulenc Agrochimie | Nye 1-(2-pyridyl)pyrazolforbindelser til kontroll av skadeinsekter |
| AU1988692A (en) * | 1991-04-24 | 1992-12-21 | E.I. Du Pont De Nemours And Company | Fungicidal pyrazoles, pyrazolines and tetrahydropyridazines |
| FR2682379B1 (fr) * | 1991-10-09 | 1994-02-11 | Rhone Poulenc Agrochimie | Nouveaux phenylpyrazoles fongicides. |
| US5550147A (en) * | 1992-02-05 | 1996-08-27 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same |
| IL104311A (en) * | 1992-02-05 | 1997-07-13 | Fujisawa Pharmaceutical Co | Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
| FR2690440B1 (fr) * | 1992-04-27 | 1995-05-19 | Rhone Poulenc Agrochimie | Arylpyrazoles fongicides. |
| FR2713225B1 (fr) * | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
| FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US6492413B2 (en) | 1993-01-15 | 2002-12-10 | G.D. Searle & Co. | 3.4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents |
| GB9420616D0 (en) * | 1994-10-12 | 1994-11-30 | Merck Sharp & Dohme | Method, compositions and use |
| US5380738A (en) * | 1993-05-21 | 1995-01-10 | Monsanto Company | 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents |
| US5840746A (en) * | 1993-06-24 | 1998-11-24 | Merck Frosst Canada, Inc. | Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases |
| US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| US5387602A (en) * | 1993-08-30 | 1995-02-07 | Ortho Pharmaceutical Corporation | 1.5-diphenyl-3-(N-hydroxycarbamoyloxyalkyl)pyrazoles |
| FR2711140B1 (fr) * | 1993-10-12 | 1996-01-05 | Sanofi Sa | 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant. |
| US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| US5434178A (en) | 1993-11-30 | 1995-07-18 | G.D. Searle & Co. | 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation |
| US5475018A (en) | 1993-11-30 | 1995-12-12 | G. D. Searle & Co. | 1,5-diphenyl pyrazole compounds for treatment of inflammation |
| US6492411B1 (en) | 1993-11-30 | 2002-12-10 | G. D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
| US6716991B1 (en) * | 1993-11-30 | 2004-04-06 | G. D. Searle & Co. | Process for preparing a substituted pyrazolyl benzenesulfonamide for the treatment of inflammation |
| US5401765A (en) * | 1993-11-30 | 1995-03-28 | G. D. Searle | 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders |
| RO118291B1 (ro) * | 1993-11-30 | 2003-04-30 | Searle & Co | Derivati de pirazol 1,3,4,5 - tetrasubstituiti si compozitie farmaceutica care ii contine |
| US5500439A (en) * | 1993-12-09 | 1996-03-19 | Alteon Inc. | Aminopyrazoles |
| US5486534A (en) * | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
| US5908852A (en) * | 1994-11-14 | 1999-06-01 | G. D. Searle & Co. | 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation |
| JP2636819B2 (ja) | 1994-12-20 | 1997-07-30 | 日本たばこ産業株式会社 | オキサゾール系複素環式芳香族化合物 |
| CZ292320B6 (cs) * | 1995-05-25 | 2003-09-17 | G. D. Searle & Co. | Způsob přípravy pyrazolů |
| CA2223154A1 (fr) * | 1995-06-02 | 1996-12-05 | G.D. Searle & Co. | Derives heterocyclo-substitues d'acide hydroxamique utilises comme inhibiteurs de la cyclo-oxygenase-2 et de la 5-lipoxygenase |
| US6515014B2 (en) | 1995-06-02 | 2003-02-04 | G. D. Searle & Co. | Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
| US6512121B2 (en) | 1998-09-14 | 2003-01-28 | G.D. Searle & Co. | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
| US5756529A (en) * | 1995-09-29 | 1998-05-26 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies |
| GB9520584D0 (en) * | 1995-10-09 | 1995-12-13 | Fujisawa Pharmaceutical Co | Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same |
| FR2742148B1 (fr) * | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
| US5908858A (en) * | 1996-04-05 | 1999-06-01 | Sankyo Company, Limited | 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses |
| US6677364B2 (en) * | 1998-04-20 | 2004-01-13 | G.D. Searle & Co. | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
| CZ225699A3 (cs) * | 1996-12-23 | 2000-09-13 | Du Pont Pharmaceuticals Company | Dusíkaté heteroaromatické sloučeniny jako inhibitory faktoru Xa |
| JPH10324639A (ja) | 1997-03-21 | 1998-12-08 | Chugai Pharmaceut Co Ltd | Il−6アンタゴニストを有効成分として含有する感作t細胞関与疾患の予防・治療剤 |
| US6979686B1 (en) | 2001-12-07 | 2005-12-27 | Pharmacia Corporation | Substituted pyrazoles as p38 kinase inhibitors |
| EP0983260A2 (fr) * | 1997-05-22 | 2000-03-08 | G.D. Searle & Co. | PYRAZOLES 3(5)-HETEROARYL SUBSTITUEES UTILISEES COMME INHIBITEURS DE KINASE p38 |
| CA2288787A1 (fr) | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | Derives de pyrazole comme inhibiteurs de kinase p38 |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| US6087496A (en) | 1998-05-22 | 2000-07-11 | G. D. Searle & Co. | Substituted pyrazoles suitable as p38 kinase inhibitors |
| HUP0003906A2 (hu) * | 1997-06-19 | 2001-05-28 | Du Pont Pharmaceuticals Co. | Xa faktort gátló hatású heterociklusos vegyületek és ezeket tartalmazó gyógyszerkészítmények |
| US5998424A (en) | 1997-06-19 | 1999-12-07 | Dupont Pharmaceuticals Company | Inhibitors of factor Xa with a neutral P1 specificity group |
| AUPO941497A0 (en) * | 1997-09-24 | 1997-10-16 | Fujisawa Pharmaceutical Co., Ltd. | Novel compounds |
| AU750356B2 (en) * | 1997-09-24 | 2002-07-18 | Fujisawa Pharmaceutical Co., Ltd. | 1,5-diphenylpyrazole derivatives |
| AU751139B2 (en) | 1997-10-13 | 2002-08-08 | Astellas Pharma Inc. | Amide derivative |
| AUPP042397A0 (en) * | 1997-11-18 | 1997-12-11 | Fujisawa Pharmaceutical Co., Ltd. | 5-arylpyrazole compounds |
| ES2137138B1 (es) * | 1998-05-29 | 2000-09-16 | Esteve Labor Dr | Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos. |
| US6306891B1 (en) | 1998-06-03 | 2001-10-23 | Merck & Co., Inc. | HIV integrase inhibitors |
| US6380249B1 (en) | 1998-06-03 | 2002-04-30 | Merck & Co., Inc. | HIV integrase inhibitors |
| US6262055B1 (en) * | 1998-06-03 | 2001-07-17 | Merck & Co., Inc. | HIV integrase inhibitors |
| AU4225499A (en) * | 1998-06-03 | 1999-12-20 | Merck & Co., Inc. | Hiv integrase inhibitors |
| US6506747B1 (en) * | 1998-06-05 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents |
| US6294558B1 (en) | 1999-05-31 | 2001-09-25 | Pfizer Inc. | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents |
| US6727238B2 (en) | 1998-06-11 | 2004-04-27 | Pfizer Inc. | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents |
| TNSN99111A1 (fr) * | 1998-06-11 | 2005-11-10 | Pfizer | Derives de sulfonylbenzene nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| DE19831656A1 (de) * | 1998-07-15 | 2000-01-20 | Basf Ag | Verfahren zur Herstellung von Pyrazolen |
| GB9816358D0 (en) * | 1998-07-27 | 1998-09-23 | Angeletti P Ist Richerche Bio | Enzyme inhibitors |
| WO2000006529A1 (fr) | 1998-07-27 | 2000-02-10 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti S.P.A. | Derives de dicetoacides utilises comme inhibiteurs de polymerases |
| USRE39708E1 (en) | 1998-08-07 | 2007-06-26 | Chiron Corporation | Estrogen receptor modulators |
| US6291190B1 (en) * | 1998-08-25 | 2001-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | Molecular differences between species of the M. tuberculosis complex |
| US6191147B1 (en) * | 1998-12-24 | 2001-02-20 | Ppd Discovery, Inc. | Pyrazole compounds and uses thereof |
| NZ512184A (en) | 1998-12-25 | 2003-08-29 | Shionogi & Co | Aromatic heterocycle compounds having HIV integrase inhibiting activities |
| DE19904397A1 (de) * | 1999-02-04 | 2000-08-10 | Bayer Ag | Verwendung von Pyrazol-Carbonsäureamiden |
| KR20020015308A (ko) * | 1999-03-26 | 2002-02-27 | 추후보정 | 아릴 치환된 피라졸, 이미다졸, 옥사졸, 티아졸 및 피롤,및 이의 용도 |
| ES2222919T3 (es) * | 1999-08-27 | 2005-02-16 | Abbott Laboratories | Compuestos sulfonilfenilpirazoles utiles como inhibidores de cox-2. |
| CA2392931A1 (fr) * | 1999-12-03 | 2001-06-07 | Pfizer Products Inc. | Derive heterocyclo-alkylsulfonyle pyrazole en tant qu'agents anti-inflammatoires/analgesiques |
| PT1104760E (pt) | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios |
| ATE252576T1 (de) | 1999-12-03 | 2003-11-15 | Pfizer Prod Inc | Heteroarylphenylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel |
| EP1104758B1 (fr) | 1999-12-03 | 2003-07-23 | Pfizer Products Inc. | Dérives acétylènes anti-inflammatoires et/ou analgésiques |
| US6569885B1 (en) * | 1999-12-23 | 2003-05-27 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
| US6372752B1 (en) * | 2000-02-07 | 2002-04-16 | Genzyme Corporation | Inha inhibitors and methods of use thereof |
| AU3217501A (en) | 2000-03-03 | 2001-09-12 | Pfizer Prod Inc | Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
| BR0108819A (pt) | 2000-03-24 | 2002-12-10 | Euro Celtique Sa | Pirazóis triazóis e tetrazóis substituìdos de arila, e o uso dos mesmos |
| WO2002055502A1 (fr) * | 2001-01-02 | 2002-07-18 | Fujisawa Pharmaceutical Co., Ltd. | Derives de pyridine utiles en tant qu'inhibiteurs de cyclo-oxygenase |
| US20030105144A1 (en) | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
| US6673818B2 (en) * | 2001-04-20 | 2004-01-06 | Pharmacia Corporation | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation |
| EP1406632A4 (fr) * | 2001-06-08 | 2009-11-04 | Cytovia Inc | 3-aryl-5-aryl- 1,2,4 -oxadiazoles et leurs analogues, activateurs des caspases et inducteurs de l'apoptose, et leurs utilisations |
| EP1273582B1 (fr) | 2001-07-05 | 2005-06-29 | Pfizer Products Inc. | Pyrazoles heterocycliques alkylsulfoniques comme agents anti-inflammatoires/analgésiques |
| US7076539B2 (en) * | 2001-07-30 | 2006-07-11 | Hewlett-Packard Development Company, L.P. | Network connectivity establishment at user log-in |
| WO2003027075A2 (fr) * | 2001-09-19 | 2003-04-03 | Pharmacia Corporation | Composes substitues de sulfamide benzene de pyrazolyl destines au traitement des inflammations |
| US6956052B2 (en) * | 2001-09-19 | 2005-10-18 | Pharmacia Corporation | Substituted pyrazolyl compounds for the treatment of inflammation |
| US7057049B2 (en) * | 2001-09-25 | 2006-06-06 | Pharmacia Corporation | Process for making substituted pyrazoles |
| RU2277534C2 (ru) * | 2001-09-25 | 2006-06-10 | Фармация Корпорейшн | Способ получения замещенных пиразолов |
| US6897318B2 (en) | 2001-09-25 | 2005-05-24 | Pharmacia Corporation | Process for making substituted pyrazoles |
| GT200200183A (es) | 2001-09-28 | 2003-05-23 | Procedimiento para preparar derivados de heterocicloalquilsulfonil pirazol | |
| WO2003037336A1 (fr) | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | Derives de 1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile et autres composes utilises en tant qu'inhibiteurs de la cyclooxygenase dans le traitement de l'arthrite, de la neurodegeneration et du cancer du colon |
| CA2468266A1 (fr) | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Inhibiteurs mitotiques de la kinesine |
| CA2477931C (fr) * | 2002-03-05 | 2011-02-01 | Josef Ehrenfreund | O-cyclopropyle-carboxanilides et leur utilisation comme fongicides |
| JP4399269B2 (ja) * | 2002-03-08 | 2010-01-13 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂性キネシン阻害薬 |
| AR038967A1 (es) * | 2002-03-18 | 2005-02-02 | Solvay Pharm Bv | Derivados de 2,3 - diaril - pirazolidinas como inhibidores de enzimas que degradan la neurotensina |
| US7329401B2 (en) * | 2002-04-15 | 2008-02-12 | The Regents Of The University Of California | Cyclooxygenase-2 selective agents useful as imaging probes and related methods |
| KR20050013553A (ko) | 2002-05-24 | 2005-02-04 | 파마시아 코포레이션 | 디아릴 피라졸의 합성 |
| IL165624A0 (en) * | 2002-06-14 | 2006-01-15 | Merck & Co Inc | Mitotic kinesin inhibitors |
| CA2492066A1 (fr) * | 2002-06-28 | 2004-01-08 | Nitromed, Inc. | Inhibiteurs a selectivite cyclooxygenase-2 nitrosiles et/ou nitroses contenant une oxime et/ou une hydrazone, compositions et methodes d'utilisation correspondantes |
| US20050004122A1 (en) * | 2002-08-14 | 2005-01-06 | Brown Bradley B. | Prenylation inhibitors containing dimethylcyclobutane and methods of their synthesis and use |
| US6649638B1 (en) * | 2002-08-14 | 2003-11-18 | Ppd Discovery, Inc. | Prenylation inhibitors and methods of their synthesis and use |
| EP1534680B1 (fr) * | 2002-08-14 | 2012-02-22 | Pharmaco Investments, Inc. | Inhibiteurs de prenylation et leurs methodes de synthese et d'utilisation |
| CA2502511A1 (fr) * | 2002-10-18 | 2004-05-29 | Pfizer Products Inc. | Ligands des recepteurs des cannabinoides et applications de ceux-ci |
| US7129239B2 (en) * | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| MXPA05005742A (es) * | 2002-12-02 | 2005-08-16 | Astellas Pharma Inc | Derivados de pirazol utiles como inhibidores de cox-i. |
| US7247628B2 (en) * | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| EP1581213A4 (fr) * | 2002-12-18 | 2008-11-19 | Cytovia Inc | 3,5-disubstitues- 1,2,4 -oxadiazoles et analogues servant d'activateurs des caspases et de promoteurs de l'apoptose, et leur utilisation |
| US7329658B2 (en) * | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| ZA200505734B (en) * | 2003-02-07 | 2006-12-27 | Daiichi Seiyaku Co | Pyrazole Derivative |
| WO2004069824A1 (fr) * | 2003-02-07 | 2004-08-19 | Daiichi Pharmaceutical Co., Ltd. | Derive de pyrazole |
| US7176210B2 (en) * | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7145012B2 (en) * | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US20040214856A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7268133B2 (en) * | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
| US7141669B2 (en) * | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
| WO2004099157A1 (fr) * | 2003-05-07 | 2004-11-18 | Pfizer Products Inc. | Ligands de recepteurs cannabinoides et leurs applications |
| US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| US20040259887A1 (en) * | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| EP1656133A4 (fr) | 2003-08-15 | 2008-10-29 | Merck & Co Inc | Inhibiteurs de kinesine mitotique |
| CN1835756A (zh) | 2003-08-15 | 2006-09-20 | 默克公司 | 有丝分裂驱动蛋白抑制剂 |
| US20060079566A1 (en) * | 2003-10-03 | 2006-04-13 | Ching-Shih Chen | PDK-1/Akt signaling inhibitors |
| TW200526641A (en) * | 2003-12-26 | 2005-08-16 | Daiichi Seiyaku Co | Amidopyrazole derivatives |
| JP2007084437A (ja) * | 2003-12-26 | 2007-04-05 | Dai Ichi Seiyaku Co Ltd | アミノアルキルピラゾール誘導体 |
| US7553838B2 (en) * | 2004-07-01 | 2009-06-30 | Merck & Co. Inc. | Mitotic kinesin inhibitors |
| MXPA06015275A (es) | 2004-07-01 | 2007-03-15 | Merck & Co Inc | Inhibidores de quinasa mitotica. |
| EP1773326A4 (fr) * | 2004-07-01 | 2009-07-22 | Merck & Co Inc | Inhibiteurs de la kinesine mitotique |
| JP2008505090A (ja) * | 2004-07-01 | 2008-02-21 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂キネシン阻害剤のプロドラッグ |
| KR20070048771A (ko) * | 2004-08-06 | 2007-05-09 | 다이이찌 세이야꾸 가부시기가이샤 | 피라졸 유도체 |
| KR20070046099A (ko) * | 2004-08-06 | 2007-05-02 | 다이이찌 세이야꾸 가부시기가이샤 | 항혈소판약 및 그의 제조방법 |
| EP1868601A4 (fr) * | 2005-04-07 | 2008-12-10 | Merck & Co Inc | Inhibiteurs de kinesine mitotique |
| EP1888050B1 (fr) | 2005-05-17 | 2012-03-21 | Merck Sharp & Dohme Ltd. | Acide cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl) cyclohexanepropanoique pour le traitement du cancer |
| EP1928859A1 (fr) * | 2005-06-17 | 2008-06-11 | Carex SA | Derives de pyrazole utilises comme modulateurs du recepteur cannabinoide |
| EP1910307A1 (fr) * | 2005-06-27 | 2008-04-16 | Exelixis, Inc. | Modulateurs des lxr a base de pyrazoles |
| TW200804345A (en) | 2005-08-30 | 2008-01-16 | Novartis Ag | Substituted benzimidazoles and methods of preparation |
| US20090062302A1 (en) | 2006-01-24 | 2009-03-05 | Buser-Doepner Carolyn A | Jak2 Tyrosine Kinase Inhibition |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| RS56600B1 (sr) | 2006-04-19 | 2018-02-28 | Novartis Ag | 6-o-supstituisana jedinjenja benzoksazola i benzotiazola i postupci inhibicije csf-1r signalinga |
| EP2698157B1 (fr) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras |
| EP2097410A4 (fr) * | 2006-09-29 | 2009-11-25 | Green Cross Corp | Dérivés d'hétéroaryl-pyrazole utilisés en tant qu'antagonistes du récepteur cb1 des cannabinoïdes |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| RS51780B (sr) | 2007-01-10 | 2011-12-31 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. | Indazoli supstituisani amidom kao inhibitori poli(adp-riboza)polimeraze (parp) |
| JP2010516679A (ja) * | 2007-01-19 | 2010-05-20 | マリンクロット インコーポレイテッド | 診断用および治療用シクロオキシゲナーゼ−2結合リガンド |
| US20080207704A1 (en) * | 2007-02-27 | 2008-08-28 | The Green Cross Corporation | Heteroaryl-imidazole derivatives as cannabinoid cb1 receptor antagonists |
| CN101679266B (zh) | 2007-03-01 | 2015-05-06 | 诺华股份有限公司 | Pim激酶抑制剂及其应用方法 |
| WO2008129280A1 (fr) * | 2007-04-20 | 2008-10-30 | Biolipox Ab | Pyrazoles utiles dans le traitement de l'inflammation |
| AU2008254425A1 (en) | 2007-05-21 | 2008-11-27 | Novartis Ag | CSF-1R inhibitors, compositions, and methods of use |
| CA2687176C (fr) * | 2007-05-31 | 2015-06-30 | Syngenta Limited | Procede de fabrication de pyrazoles |
| WO2009002495A1 (fr) | 2007-06-27 | 2008-12-31 | Merck & Co., Inc. | Dérivés de 4-carboxybenzylamino utilisés en tant qu'inhibiteurs de l'histone désacétylase |
| US8039502B2 (en) | 2007-07-24 | 2011-10-18 | The Ohio State University Research Foundation | Anti-infective agents against intracellular pathogens |
| US7977358B2 (en) * | 2007-07-26 | 2011-07-12 | Hoffmann-La Roche Inc. | Pyrazol derivatives |
| CA2699157A1 (fr) | 2007-09-10 | 2009-03-19 | Calcimedica, Inc. | Composes modulant le calcium intracellulaire |
| WO2009051772A1 (fr) * | 2007-10-17 | 2009-04-23 | Duke University | Inhibiteurs de géranylgéranyl transférase et méthodes de production et d'utilisation de ces derniers |
| WO2009078498A1 (fr) * | 2007-12-17 | 2009-06-25 | Green Cross Corporation | Biarylpyrazole-4-carboxamides comme ligands des récepteurs cannabinoïdes cb1 |
| WO2009094224A1 (fr) | 2008-01-25 | 2009-07-30 | Millennium Pharmaceuticals, Inc. | Thiophènes et leurs utilisations |
| AU2009222122A1 (en) | 2008-03-03 | 2009-09-11 | Tiger Pharmatech | Tyrosine kinase inhibitors |
| DE102008015032A1 (de) | 2008-03-17 | 2009-09-24 | Aicuris Gmbh & Co. Kg | Substituierte Pyrazolamide und ihre Verwendung |
| DE102008015033A1 (de) * | 2008-03-17 | 2009-09-24 | Aicuris Gmbh & Co. Kg | Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung |
| DK2307381T3 (da) * | 2008-06-09 | 2021-03-15 | Univ Muenchen Ludwig Maximilians | Nye lægemidler til inhibering af aggregering af proteiner involveret i sygdomme forbundet med proteinaggregering og/eller neurodegenerative sygdomme |
| JP2011524872A (ja) * | 2008-06-11 | 2011-09-08 | メルク・シャープ・エンド・ドーム・コーポレイション | Faahの阻害剤として有用なピラゾール誘導体 |
| EP2321303B1 (fr) | 2008-08-27 | 2019-11-27 | Calcimedica, Inc. | Composés qui modulent le calcium intracellulaire |
| DE102008062863A1 (de) | 2008-12-17 | 2010-06-24 | Aicuris Gmbh & Co. Kg | Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung |
| DE102008062878A1 (de) | 2008-12-17 | 2010-06-24 | Aicuris Gmbh & Co. Kg | Substituierte Furancarboxamide und ihre Verwendung |
| US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| US9139589B2 (en) | 2009-01-30 | 2015-09-22 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
| US20120108823A1 (en) | 2009-04-22 | 2012-05-03 | The Ohio State University Research Foundation | Anti-francisella agents |
| DE102009036604A1 (de) | 2009-07-30 | 2011-02-03 | Aicuris Gmbh & Co. Kg | Substituierte Bis-Arylpyrazolamide mit terminaler primärer Amidfunktionalisierung und ihre Verwendung |
| UA109417C2 (uk) | 2009-10-14 | 2015-08-25 | Мерк Шарп Енд Доме Корп. | ЗАМІЩЕНІ ПІПЕРИДИНИ, ЯКІ ПІДВИЩУЮТЬ АКТИВНІСТЬ p53, І ЇХ ЗАСТОСУВАННЯ |
| PT2563776T (pt) | 2010-04-27 | 2016-09-19 | Calcimedica Inc | Compostos que modulam o cálcio intracelular |
| CA2797533A1 (fr) | 2010-04-27 | 2011-11-10 | Calcimedica, Inc. | Composes qui modulent le calcium intracellulaire |
| US8999957B2 (en) | 2010-06-24 | 2015-04-07 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as ERK inhibitors |
| CN103068980B (zh) | 2010-08-02 | 2017-04-05 | 瑟纳治疗公司 | 使用短干扰核酸(siNA)的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1(CTNNB1)基因表达的抑制 |
| WO2012021611A1 (fr) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Hétéroaryles et utilisations de ceux-ci |
| TW201217365A (en) | 2010-08-11 | 2012-05-01 | Millennium Pharm Inc | Heteroaryls and uses thereof |
| EP2603216A4 (fr) | 2010-08-11 | 2013-12-18 | Millennium Pharm Inc | Hétéroaryles et utilisations |
| LT2606134T (lt) | 2010-08-17 | 2019-07-25 | Sirna Therapeutics, Inc. | Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina) |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| CN106905311A (zh) | 2010-08-27 | 2017-06-30 | 钙医学公司 | 调节细胞内钙的化合物 |
| US8580805B2 (en) * | 2010-08-31 | 2013-11-12 | Hubert Maehr | Pyrimidine carboxamide derivatives |
| US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| EP2615916B1 (fr) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk |
| UY33671A (es) | 2010-10-13 | 2012-04-30 | Millenium Pharmaceuticals Inc | Heteroarilos y sus usos |
| EP2632472B1 (fr) | 2010-10-29 | 2017-12-13 | Sirna Therapeutics, Inc. | Inhibition facilitée par l'interférence d'arn de l'expression d'un gène au moyen d'acides nucléiques interférents courts (sina) |
| US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| WO2012143879A1 (fr) | 2011-04-21 | 2012-10-26 | Piramal Healthcare Limited | Forme cristalline d'un sel d'un dérivé de morpholinosulfonylindole et son procédé de préparation |
| US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
| WO2013066729A1 (fr) | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Aminopyrimidinones en tant qu'inhibiteurs de kinases associées au récepteur de l'interleukine |
| DE102011055815A1 (de) | 2011-11-29 | 2013-05-29 | Aicuris Gmbh & Co. Kg | Carboxamid-substituierte Heteroaryl-Pyrazole und ihre Verwendung |
| WO2013096642A1 (fr) * | 2011-12-23 | 2013-06-27 | Millennium Pharmaceuticals, Inc. | Hétéroaryles et utilisations de ceux-ci |
| EP3453762B1 (fr) | 2012-05-02 | 2021-04-21 | Sirna Therapeutics, Inc. | Compositions d'acide nucléique interférent court (sina) |
| WO2014022382A2 (fr) * | 2012-07-30 | 2014-02-06 | The Ohio State University | Inhibiteurs de protéine kinase antibactérienne |
| DE102012016908A1 (de) | 2012-08-17 | 2014-02-20 | Aicuris Gmbh & Co. Kg | Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung |
| EP2900241B1 (fr) | 2012-09-28 | 2018-08-08 | Merck Sharp & Dohme Corp. | Nouveaux composés inhibiteurs de erk |
| US9512116B2 (en) | 2012-10-12 | 2016-12-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| SI2925888T1 (en) | 2012-11-28 | 2018-02-28 | Merck Sharp & Dohme Corp. | Compounds and methods for the treatment of cancer |
| TW201429969A (zh) | 2012-12-20 | 2014-08-01 | Merck Sharp & Dohme | 作爲hdm2抑制劑之經取代咪唑吡啶 |
| EP2951180B1 (fr) | 2013-01-30 | 2018-05-02 | Merck Sharp & Dohme Corp. | Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2 |
| CN103265537B (zh) * | 2013-05-14 | 2015-05-27 | 浙江医药高等专科学校 | 抗肿瘤化合物、其制备方法和用途 |
| WO2015006181A1 (fr) | 2013-07-11 | 2015-01-15 | Merck Sharp & Dohme Corp. | Inhibiteurs amidopyrazole substitués de kinases associées aux récepteurs de l'interleukine (irak -4) |
| ES2656475T3 (es) | 2013-07-31 | 2018-02-27 | Council Of Scientific & Industrial Research | Nuevos compuestos de indazol y un proceso para la preparación de éstos |
| EP3041938A1 (fr) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Polynucléotides circulaires |
| US9611263B2 (en) | 2013-10-08 | 2017-04-04 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
| KR101650476B1 (ko) * | 2015-02-06 | 2016-08-23 | 한국건설기술연구원 | 중공슬래브를 위한 중공체의 부력방지장치 |
| EP3268367B8 (fr) | 2015-03-12 | 2022-11-16 | Merck Sharp & Dohme LLC | Carboxamides utilisés comme inhibiteurs de l'activité de l'irak4 |
| EP3267996B1 (fr) | 2015-03-12 | 2020-11-11 | Merck Sharp & Dohme Corp. | Inhibiteurs de l'activité d'irak4 à base de pyrazolopyrimidine |
| US10040802B2 (en) | 2015-03-12 | 2018-08-07 | Merck Sharp & Dohme Corp. | Thienopyrazine inhibitors of IRAK4 activity |
| EP3525785B1 (fr) | 2016-10-12 | 2025-08-27 | Merck Sharp & Dohme LLC | Inhibiteurs de kdm5 |
| TWI794294B (zh) * | 2017-09-13 | 2023-03-01 | 南韓商韓美藥品股份有限公司 | 吡唑衍生化合物及其用途 |
| WO2019094312A1 (fr) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
| EP3706742B1 (fr) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Inhibiteurs de prmt5 |
| WO2020033284A1 (fr) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
| EP3833668B1 (fr) | 2018-08-07 | 2025-03-19 | Merck Sharp & Dohme LLC | Inhibiteurs de prmt5 |
| US12173026B2 (en) | 2018-08-07 | 2024-12-24 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| US12479816B2 (en) | 2019-02-08 | 2025-11-25 | University of Pittsburgh—of the Commonwealth System of Higher Education | 20-HETE formation inhibitors |
| CA3160153A1 (fr) | 2019-12-17 | 2021-06-24 | Michelle Machacek | Inhibiteurs de prmt5 |
| EP4076460A4 (fr) | 2019-12-17 | 2023-11-15 | Merck Sharp & Dohme LLC | Inhibiteurs de prmt5 |
| WO2021126728A1 (fr) | 2019-12-17 | 2021-06-24 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
| CN112961109B (zh) * | 2021-01-27 | 2022-05-17 | 台州学院 | 一种1,4-双磺酰化的全取代吡唑类化合物及其制备和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4146721A (en) * | 1969-09-12 | 1979-03-27 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pyrazol-4-acetic acid compounds |
| DE2536003C2 (de) * | 1975-08-08 | 1985-11-14 | Schering AG, 1000 Berlin und 4709 Bergkamen | Pyrazol-Derivate, ihre Herstellung und diese enthaltende pharmazeutische Derivate |
| DE2906252A1 (de) * | 1979-02-19 | 1980-08-28 | Merck Patent Gmbh | Pyrazolderivate, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung |
| CA1130808A (fr) * | 1979-10-05 | 1982-08-31 | Ronald G. Micetich | 3-(ou 5-) trifluoromethyl-1-aryl pyrazoles |
| JPS58177977A (ja) * | 1982-04-09 | 1983-10-18 | Grelan Pharmaceut Co Ltd | 4−フエニルピラゾ−ル類 |
| DE3575130D1 (de) * | 1984-05-12 | 1990-02-08 | Fisons Plc | Antiinflammatorische 1,n-diarylpyrazol-3-amine, deren zusammensetzungen und verfahren zu deren herstellung. |
| JPS6140266A (ja) * | 1984-08-01 | 1986-02-26 | Morishita Seiyaku Kk | ピラゾ−ル誘導体 |
| US4826868A (en) * | 1986-05-29 | 1989-05-02 | Ortho Pharmaceutical Corporation | 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use |
| US5078780A (en) * | 1986-10-22 | 1992-01-07 | Ciba-Geigy Corporation | 1,5-diphenylpyrazole-3-carboxylic acid derivatives for the protection of cultivated plants |
| EP0272704A3 (fr) * | 1986-12-26 | 1990-11-22 | Sanwa Kagaku Kenkyusho Co., Ltd. | Emploi de dérivés de pyrazole pour le traitement de troubles de l'immunité et de la néphropathie |
| JPS6425763A (en) * | 1987-04-24 | 1989-01-27 | Mitsubishi Chem Ind | Pyrazoles and insecticide and acaricide containing said pyrazoles as active ingredient |
| AU611437B2 (en) * | 1987-05-29 | 1991-06-13 | Ortho Pharmaceutical Corporation | Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-n-hydroxypropanamides and method for synthesizing the same |
| JPH089541B2 (ja) * | 1988-03-07 | 1996-01-31 | 三井東圧化学株式会社 | ピラゾール類を主成分とする脳浮腫抑制剤 |
-
1990
- 1990-09-11 PH PH41179A patent/PH27357A/en unknown
- 1990-09-13 IL IL9567590A patent/IL95675A/en not_active IP Right Cessation
- 1990-09-14 US US07/582,358 patent/US5134142A/en not_active Expired - Lifetime
- 1990-09-18 CA CA002025599A patent/CA2025599C/fr not_active Expired - Fee Related
- 1990-09-18 IE IE337990A patent/IE68857B1/en not_active IP Right Cessation
- 1990-09-19 DK DK90117983.8T patent/DK0418845T3/da active
- 1990-09-19 AT AT90117983T patent/ATE126216T1/de not_active IP Right Cessation
- 1990-09-19 FI FI904602A patent/FI102535B/fi not_active IP Right Cessation
- 1990-09-19 ES ES90117983T patent/ES2088933T3/es not_active Expired - Lifetime
- 1990-09-19 HU HU905970A patent/HU208122B/hu not_active IP Right Cessation
- 1990-09-19 DE DE69021472T patent/DE69021472T2/de not_active Expired - Fee Related
- 1990-09-19 EP EP90117983A patent/EP0418845B1/fr not_active Expired - Lifetime
- 1990-09-20 JP JP2252319A patent/JP2586713B2/ja not_active Expired - Fee Related
- 1990-09-21 RU SU4831230/04A patent/RU2021990C1/ru not_active IP Right Cessation
- 1990-09-21 CN CN90107130A patent/CN1046506C/zh not_active Expired - Fee Related
- 1990-09-21 NO NO904134A patent/NO301006B1/no not_active IP Right Cessation
- 1990-09-21 PT PT95389A patent/PT95389B/pt not_active IP Right Cessation
- 1990-09-21 AU AU63072/90A patent/AU637142B2/en not_active Ceased
- 1990-09-21 KR KR1019900015110A patent/KR0182798B1/ko not_active Expired - Fee Related
-
1991
- 1991-12-02 RU SU915010250A patent/RU2059622C1/ru active
-
1995
- 1995-06-22 HU HU95P/P00344P patent/HU211532A9/hu unknown
- 1995-08-10 GR GR950402078T patent/GR3017100T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0418845B1 (fr) | Dérivés de pyrazole, leur procédé de préparation et composition pharmaceutique les contenant | |
| US6506747B1 (en) | Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents | |
| ES2393950T3 (es) | Inhibidores de la quinasa P38 con base en heterociclos de 5 miembros | |
| CN1867336B (zh) | 1-芳基-4-取代的哌嗪衍生物及其制药用途 | |
| AU663149B2 (en) | Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same | |
| US8420689B2 (en) | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation | |
| US5550147A (en) | Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same | |
| JP3457669B2 (ja) | 新規な1,2−ベンゾイソオキサゾール誘導体またはその塩,それらからなる脳保護剤 | |
| JPH0625134B2 (ja) | 新規な複素環化合物 | |
| MXPA06013593A (es) | Nuevos derivados de piridazin-3(2h)-ona. | |
| JP2006199710A (ja) | 置換イミダゾール神経ペプチドyy5レセプタアンタゴニスト | |
| KR20110130388A (ko) | 제약 화합물 | |
| CA2234511A1 (fr) | Pyrazoles 1,3,5-trisubstitues pour le traitement des inflammations | |
| JPWO1994010158A1 (ja) | 新規な1,2−ベンゾイソオキサゾール誘導体またはその塩,それらからなる脳保護剤 | |
| US6548512B1 (en) | Nitrogen containing heteroaromatics as factor Xa inhibitors | |
| WO1999025695A1 (fr) | Composes 5-arylpyrazole | |
| AU2004200420A1 (en) | Inhibitor of cyclooxygenase | |
| MXPA00011920A (en) | Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents | |
| HK1099206B (en) | 1-aryl-4-substituted piperazine derivatives and their uses in manufacturing medicaments | |
| BRPI0613309A2 (pt) | composto, composição farmacêutica, método para a fabricação de uma composição farmacêutica, método para evitar, melhorar ou tratar uma doença, distúrbio ou sìndrome mediada por receptor de canabinóide, agonista seletivo de cb2, uso de um composto e processo para preparar um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |